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ABSTRACT
THE IMPORTANCE OF NONCAPPED VIRAL GENOMIC RNA TO ALPHAVIRAL
INFECTION AND PATHOGENESIS
Autumn LaPointe
March 25, 2021
Alphaviruses are mosquito-borne arboviruses that have a positive sense,
single-stranded RNA genome, which are capable of causing severe disease and
thus pose a significant burden to public health. During alphaviral replication,
significant quantities of viral genomic RNAs that lack the canonical alphaviral 5’
cap structure are produced and packaged into viral particles, despite the fact that
these noncapped genomes cannot be translated and are essentially
noninfectious. The production and packaging of the noncapped genomes has
been found to be true for infections across multiple vertebrate and invertebrate
cell lines and alphavirus species, although the proportion of ncgRNA produced
differs. Despite knowing this, the importance of the noncapped genomic vRNA
(ncgRNA) to alphaviral infection has yet to be fully characterized. In this
dissertation, the importance of the ncgRNAs to alphaviral infection was assessed
by using mutations of the nsP1 protein of Sindbis virus (SINV), which altered the
synthesis of the ncgRNAs during infection by modulating the protein’s capping
efficiency. It was found that decreasing ncgRNA production lead to decreased
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viral growth kinetics via decreased particle production; whereas increasing
ncgRNA production led to wild type growth kinetics and particle production.
In addition to being necessary for efficient viral replication in vitro, we also
found that the noncapped genomic RNA was critical for alphaviral pathogenesis.
Mice infected with the increased ncgRNA mutant exhibited wild type rates weight
loss, and neurological symptoms, but exhibited a slight decrease in mortality.
Conversely, the mice infected with the decreased ncgRNA mutant showed
significantly reduced mortality and morbidity compared to mice infected with wild
type virus. Interestingly, both mutants had modestly reduced viral titer in the brain
compared to wild type virus. Importantly, examination of the brain tissue revealed
that mice infected with the decreased ncgRNA mutant had significantly reduced
cell death, immune cell infiltration, and expression of proinflammatory cytokines
compared to the increased ncgRNA mutant and wild type virus.
Collectively, these data indicate that the ncgRNA play an important role
during alphaviral replication and pathogenesis by increasing the efficiency of
particle production and modulating the host immune response.
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CHAPTER 1
INTRODUCTION

Alphaviruses as Pathogens
Alphaviruses are mosquito-borne, single-stranded RNA viruses that have
been the cause of both localized outbreaks and large epidemics of severe
disease. Transmission of these viruses largely occurs between a mosquito
vector, primarily Aedes, Anopheles, and Culex genera, and a vertebrate host,
typically rodents and birds, in an enzootic cycle (Fig. 1.1) [1]. However, epizootic
spillover events do occur that lead to infection of humans and horses. Although
these tend to be dead-end hosts, recent alphavirus epidemics have shown the
ability of these viruses to adapt for more efficient interhuman transmission [2].
Due to the expansion of the geographic area in which the mosquito vectors can
be found, alphaviruses have an increased capacity to emerge into naïve
populations, making them a significant threat to public health.
Alphaviruses are largely classified as either arthritogenic or encephalitic
based on the symptoms of infection. Arthritogenic alphaviral infection causes
disease that can vary from mild to severe and can persist for several months to
years past the acute phase of infection [3]. This includes Chikungunya (CHIKV)
and Ross River Virus (RRV) which are capable of causing debilitating
polyarthritis as well as the model alphavirus Sindbis virus (SINV), which is the
1

causative agent of rash-arthritic diseases like Pogosta disease, Ockelbo disease,
and Karelian fever [4-8]. While not associated with high rates of mortality, the
high morbidity of arthritogenic alphaviral disease results in a high economic
burden that is particularly damaging in regions where labor-intensive work is
prevalent [9, 10]. The encephalitic alphaviruses include Venezuelan, Eastern,
and Western Equine Encephalitis viruses (VEEV, EEEV, and WEEV) and are
capable of causing severe meningitis and encephalitis, as well as long lasting
sequelae such as seizures, paralysis, and cognitive deficits in survivors [11-14].
These viruses, while comparatively rare in regards to their incidence, typically
have high mortality rates, especially in comparison to the arthritogenic
alphaviruses, with viruses like EEEV having mortality rates as high as 70% in
symptomatic individuals [15].
As part of their transmission cycles, alphaviruses infect both mosquitos as
well as vertebrates. Infection of the mosquito vector begins with the ingestion of a
bloodmeal from an infected vertebrate host. Viral infection is initiated in the
midgut, where the virus infects and replicates within epithelial cells lining the gut
[16, 17]. Once the virus has escaped from the midgut, it then spreads to the
hemocoel, an open body cavity where hemolymph is circulated. Once in the
hemolymph, the virus is spread to secondary tissues, including the salivary
glands, which is the main site of viral transmission [16]. Once the salivary glands
have been infected, the virus can be released into the salivary ducts and
transmitted orally to a vertebrate host during the mosquito’s next blood meal. The
extrinsic incubation period, which is the time from ingestion of the infected
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bloodmeal to when the mosquito is able to transmit the virus, is ~2-7 days for
alphaviruses [1]. While the mosquito immune system is able to limit viral
replication, it is unable to completely clear the virus, thus allowing the virus to be
continuously transmitted to new vertebrate hosts for the life of the mosquito [18].
After being transmitted to a vertebrate host, the virus replicates locally at the site
of inoculation in the skin, specifically dermal fibroblasts, enterocytes, and
keratinocytes [19]. Infection of Langerhan’s cells and dendritic cells in the skin
leads to infection of the lymph nodes draining the site of inoculation. Once
viremia occurs, the virus is then able to disseminate to other tissues, including
lymphoid tissues, joints, and the central nervous system including the brain [1].
Which secondary organs the virus disseminates to is largely dependent on
the particular alphavirus species, as tissue tropism differs greatly among the
alphaviruses. The arthritogenic alphaviruses primarily target the cells of the skin,
joints, and muscle, while the encephalitic alphaviruses target those of the
nervous system [1]. Inflammation in these target regions in response to viral
infection then ultimately leads to the development of alphaviral disease. The time
from infection to onset of symptoms, termed the intrinsic incubation period,
ranges from 2-10 days in people for both the arthritic and encephalitic
alphaviruses [20, 21].
Despite the threat that alphaviruses pose to public health, there are no
antiviral strategies or vaccines which are either safe or effective for preventing
alphaviral infection or treating alphaviral disease. This deficit of viable
therapeutics highlights the need to better understand the mechanisms behind
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alphaviral infection in order to develop novel antiviral strategies for the mitigation
of alphaviral disease.

A Brief Overview of the Alphaviral Life Cycle
Infection begins with the E2 glycoproteins in the viral envelope binding to
receptors on the surface of the host cell (Fig. 1.2). After binding, the virus rapidly
enters the host cell via receptor mediated endocytosis, which forms an
endosome containing the viral particle [22, 23]. As the endosome transitions from
early to late, the low pH of the maturing endosome causes conformational
changes in the glycoproteins which allows the envelope to fuse with the
endosomal membrane, releasing the viral nucleocapsid into the cell cytoplasm
[24]. Membrane fusion is mediated by the viral E1 glycoprotein after the exposure
of the fusion loop during the conformational change in response to pH [25].
Following the release of the nucleocapsid core, the host 60S ribosomal RNA
interacts with the capsid protein and facilitates the disassembly of the
nucleocapsid, resulting in the viral genome being released into the cytoplasm
[26]. The genome then interacts with host factors and is immediately translated
by host cell machinery, producing the nonstructural polyprotein P1234, which is
then proteolytically cleaved via the proteolytic activities of nonstructural protein 2
(nsP2) to form the initial viral replicase complex, P123 and nsP4. This initial
complex uses the viral genome to synthesize the minus strand RNA that serves
as the template for viral replication and transcription [27]. The nonstructural
polyprotein is then further processed by nsP2 to produce the individualized
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nonstructural proteins of the fully processed viral replicase complex (consisting of
nsP1, nsP2, nsP3, and nsP4) [28]. The replicase complex produces the genomic
RNA and subgenomic RNA through viral replication and transcription,
respectively. The subgenomic RNA is translated to produce the structural
polyprotein, consisting of the capsid protein, the glycoproteins E3; E2; and E1,
and the 6K/transframe (TF) proteins. The capsid protein cleaves itself off of the
structural polyprotein and associates with the newly synthesized viral genomes to
form nucleocapsid cores [29]. The remaining structural polyprotein is targeted to
the endoplasmic reticulum via signal sequences present in the E3 protein, and
subsequently processed into the individual glycoproteins in the ER via the
activities of host proteases, where they undergo post-translational modifications
including disulfide bond rearrangement, palmitoylation, and glycosylation prior to
being trafficked to the cell surface [30]. Newly formed mature virions are then
released from the cell via budding, creating the envelope that contains the viral
glycoproteins as the nucleocapsid core pushes through the host plasma
membrane [30].

Alphavirus Genetic Organization
The alphaviral genome is a single-strand of positive sense RNA that is
~11.5kb in length and contains two coding regions. The first open reading frame
is the only one expressed from the genome and codes for the nonstructural
proteins nsP1-4, which are responsible for RNA replication (Fig. 1.3). The
nonstructural proteins are expressed as a polyprotein, P1234, that undergoes
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several iterations of proteolytic cleavage to form the various replication
complexes needed to produce the minus strand template and subgenome in
addition to more genomic RNA. The minus strand RNA, which serves as the
template from which the genome and subgenome, is the predominant vRNA
synthesized by a complex consisting of P123 and nsP4. Once the viral
polyprotein has been fully cleaved into nsP1,2,3, and 4, they form the replication
complex that synthesizes the genome and subgenome. The subgenome contains
only the second open reading frame and is responsible for the production of the
structural proteins. The structural proteins include the capsid protein,
glycoproteins, and the 6k/TF protein, which are all required to form the viral
particle.

The Alphaviral Nonstructural Proteins
As stated earlier, there are four nonstructural proteins (nsPs) encoded as
a single polyprotein during the translation of the viral genomic RNA. These are
named numerically in the order of their relative position to the N-terminus of the
polyprotein. Each of the individual nsPs are necessary for viral replication with
their primary functions in viral replication being modular in nature; and in addition
to their viral RNA synthesis roles, several of the nsPs have critical functions
outside of viral replication complex.

The Alphaviral nsP1 Protein
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The ~60kDa nsP1 protein serves three primary functions during alphaviral
infection: anchoring the replication complex, forming the pore to the replication
spherules, and vRNA capping via methyltransferase and guanylyltransferase
enzymatic reactions [28]. The presence of an amphipathic helix, and the
palmitoylation of conserved cysteine residues in nsP1, allows the protein to
anchor the replication complexes to host membranes, which is a consistent
feature of the replication machinery of all ssRNA viruses. Binding of nsP1 to the
host membrane starts with weak binding of the amphipathic helix to plasma
membrane. This is followed by palmitoylation of cysteine residues within the
amphipathic helix, which changes the properties of nsP1 to appear similar to
those of the integral membrane proteins [31]. The interaction of the nsP1 protein
with host membranes is associated with the formation of subcellular structures
important to alphaviral biology, including the formation of membranous
spherules, and the formation of filopodia at the cell surface which aid in cell-tocell transmission [31, 32]. The spherules are formed from host membranes, with
the specific host membrane varying across the members of the genus, and serve
as the site of RNA replication. In addition to anchoring the replication complex
and lining the spherule compartment, the nsP1 protein has also been shown to
form the pore structures that are in part responsible for controlling access to the
replication spherules [33]. In a recent publication from Jones et al that
determined the structure of nsP1, they demonstrated that the nsP1 proteins
assemble into a dodecameric ring structure that would allow the protein to restrict
access to the replication spherule. Whether the guanylytransferase or
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methyltransferase activities of nsP1 are active while in this pore-like structure is
unknown, but the constriction of the pore is important for keeping the dsRNA
intermediates that form during RNA replication from being sensed by host
proteins like MDA5, LGP2, and Dicer [34]. While the membrane binding
properties of the nsP1 protein are dispensable to viral replication, the efficiency
of RNA synthesis in mutants lacking membrane association is greatly impaired.
Nonetheless, nsP1’s role as a membrane binding protein is separate from its
function as the capping enzyme, as binding to the host membrane does not
impact the enzymatic activity of nsP1 [35-37].
The nsP1 protein’s role as the alphaviral capping enzyme has been fairly
well characterized. Both the genome and subgenome have a Type-0 cap
structure co-transcriptionally added to the 5’ end during RNA synthesis. The
Type-0 cap used by alphaviruses is similar to the Type-1 cap added to eukaryotic
mRNAs, with the major difference being that the Type-1 cap is 2’O methylated
whereas the Type-0 cap is not [38]. The addition of the cap to the 5’ end of the
viral RNA serves multiple critical functions in virus replication as well as how the
vRNA interacts with the host cell. The presence of the 5’ cap structure allows the
genome and subgenome to be readily translated using the host translation
machinery. In addition, the 5’ cap also protects the RNA from being degraded by
host exonucleases and prevents immune sensing of the viral RNA by host
proteins such as RIG-I.
The addition of the cap to the 5’ end of the vRNA is carried out in a
stepwise fashion by nsP1 and nsP2. The methyltransferase domain of nsP1
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transfers a methyl group from S-adenosylmethionine (SAM) to the N7 position of
a GTP molecule. The guanylyltransferase region of nsP1 then binds the m7Gppp
nucleotide forming a covalent link with the catalytic histidine residue (specifically
H39 in SINV), releasing a molecule of inorganic pyrophosphate (PPi) and
resulting in the formation of an m7GMP-nsP1 intermediate [35, 39]. By this time
the nsP2 protein has removed the 5’ γ-phosphate from the nascent vRNA, and
nsP1 transfers the m7GMP moiety to the vRNA molecule, resulting in the
formation of the Type-0 7meGppA cap structure [40]. The alphaviral RNA
capping mechanism is considered to be unconventional, as the methylation of
the GTP and the guanylyltransferase activities are in the reverse order compared
to how RNA capping occurs in eukaryotic cells, where the guanine moiety is
added to the RNA first and then methylated [38]. Importantly, and as described
in greater depth below, the capping activities of the nsP1 protein can be
modulated via the incorporation of point mutations.

The Alphaviral nsP2 Protein
The ~90kDa nsP2 protein has several distinct domains and has a diverse
range of functions during the viral lifecycle [28]. The protease domain of nsP2 is
responsible for cleaving the nonstructural polyprotein in cis- and in trans- during
viral RNA synthesis, specifically through the processing of P1234 into
P123+nsP4 via cis-cleavage, and then further cleaving P123 into nsP1+P23, and
later P23 into nsP2 and nsP3 via trans-cleavage events [41]. Viruses lacking this
proteolytic activity have been shown to be unable to complete the viral lifecycle
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as the maturation of the RNA synthetic complex is essential to viral RNA
synthesis [42]. Additionally, in regards to viral replication and transcription the
nsP2 protein functions as an RNA helicase and an RNA triphosphatase. The
helicase activity of nsP2 allows it to unwind RNA secondary structures during
viral replication [43]. As mentioned above, the RNA triphosphatase motif in nsP2
allows it to remove a phosphate from the 5’ nucleotide, which prepares the vRNA
for subsequent capping. In addition to the helicase and triphosphatase domains
the nsP2 protein has a methyltransferase domain that is presumed to be
enzymatically inactive as it lacks the catalytic residues of known
methyltransferase enzymes [44]. The precise function / importance of this
domain is unknown at this time.
In addition to the roles described above, the nsP2 protein of Old World
alphaviruses (including SINV) is intimately involved in the shutoff of host
transcription during viral infection [45]. The shutoff of host transcription, and its
importance to the evasion of the host antiviral defenses are described in greater
detail below.

The Alphaviral nsP3 Protein
Compared to the other alphaviral nonstructural proteins the alphaviral
nsP3 protein has been enigmatic, while necessary for RNA replication, the exact
roles that nsP3 plays in this process are poorly defined. Structurally the ~60kDa
nsP3 protein consists of three distinct regions- an N-terminal Macrodomain, an
Alphavirus Unique Domain (AUD), and a C-terminal hypervariable region that is
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multiply phosphorylated during infection [28]. The N-terminal Macrodomain
exhibits the highest level of sequence conservation across the members of the
genus, and is known to have ADP-ribosylase activity, which has been correlated
with its ability to disassemble and prevent stress granule formation during viral
replication [46, 47]. The importance of ADP-ribosylation is an area of current
study. Similarly, the AUD is not well understood, but mutational analyses of the
domain have indicated important roles in viral RNA synthesis, particularly in
regards to the synthesis of the subgenomic vRNAs [48]. The C-terminal
hypervariable region includes binding motifs for many host proteins and is
thought to act as a scaffold which may be important for the assembly of the
replication complex [49]. Interestingly, the hypervariable region exhibits
remarkable diversity both at the amino acid level and the identities of the specific
interacting host factors.

The Alphaviral nsP4 Protein
The ~70kDa alphaviral nsP4 protein is the viral RNA dependent RNA
polymerase (RdRp) [28]. Many alphaviruses produce less nsP4 than the other
nonstructural proteins, primarily due to the presence of a leaky Opal stop codon
at the end of nsP3 which will occasionally terminate translation before nsP4 has
been synthesized [50]. The nsP4 protein is solely responsible for carrying out
RNA synthesis; however, nsP4 cannot act on its own, and can only function
properly in association with the other nonstructural proteins as the replicase
complex [51]. Structurally the nsP4 protein is largely unremarkable when
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compared to the RdRps of other positive-sense RNA viruses. Regardless, there
are nuances specific to the alphaviral RdRp, including the absolute requirement
of an N-terminal tyrosine residue for activity, the function of which is unclear at
this time. Additionally, the alphaviral nsP4 protein is responsible for the synthesis
of the poly(A) tail found on the positives-sense vRNAs [28]. It should be noted
that the nsP4 protein lacks any discernable proof-reading capacity, resulting in a
relatively high rate of mutation and the formation of a diverse quasispecies [52].

The Alphaviral Structural Proteins
As with the nonstructural proteins, the synthesis of the structural proteins
begins with the synthesis of a polyprotein from the subgenomic vRNA from which
the individual proteins are generated via proteolytic processing events. While the
subgenomic RNA is known to be capped it is believed to utilize a noncanonical
cap-independent translation initiation mechanism [53]. This is due to the
cessation of cap-dependent translation during alphaviral infection following the
activation of the host PKR response leading to phosphorylation of eIF2α in
response to the synthesis of viral dsRNA. Regardless, the translation of the
subgenomic vRNA leads to the production of 6 structural proteins- capsid, the
E3; E2; and E1 glycoproteins, the 6k, and transframe (TF) proteins.

The Alphaviral Capsid Protein
The ~30kDa alphaviral capsid protein lacks a discernable beta-sheet jelly
roll conformation, and thus, is structurally unique compared to capsids of other
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positive-sense RNA viruses [54, 55]. Architecturally the alphaviral capsid protein
may be broadly divided into two domains- an N-terminal polybasic region with
little structure, and a well conserved C-terminal protease domain. The N-terminal
region lacks mentionable sequence conservation outside of being generally
positively charged and being relatively proline rich. Subdomains exist within the
N-terminal domain, with specific regions having known functional roles during the
alphaviral lifecycle. The N-terminal subdomain is believed to mitigate the
negative charge of the vRNA in the context of the nucleocapsid [56]. Immediately
adjacent to the RNA-binding domain is an alpha helix known to be involved in the
formation of capsid dimers during the viral assembly process. Finally, the third
subdomain exhibits a moderate degree of sequence conservation and is involved
in the selection of the viral genomic RNA during packaging as well as the release
of the genomic RNA from the nucleocapsid upon the binding of the 60S rRNA
[56, 57].
In contrast to the N-terminal domain, the C-terminal Protease domain is
rather well conserved amongst the members of the genus. The proteolytic activity
of the protease domain is responsible for the initial cleavage of the capsid protein
from the structural polyprotein, after which the C-terminal tail of the capsid
protein inactivates the protease active site via steric hindrance [58, 59].
In addition to the structural roles of the alphaviral capsid protein, the
capsid protein of New World alphaviruses are responsible for the shutoff of host
gene expression, as described in greater detail below.
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The Alphaviral Glycoproteins
After the cleavage of the capsid protein from the structural polyprotein
encoded by the subgenomic RNA the signal sequence present in the E3 protein
guides the synthesis of the remaining proteins into the host ER [60]. As with the
nonstructural polyprotein a series of proteolytic cleavage events lead to the
production of the individual viral glycoproteins; however, unlike the previous
polyprotein processing events, these cleavages utilize host proteases [61, 62].
Initially, the 6K and E1 proteins are liberated from the polyprotein via the activity
of signal peptidases, leaving the remaining polyprotein consisting of the
uncleaved E3 and E2 proteins. This sub-polyprotein, termed PE2 (or P62), is
then processed by host furin protease to form the final glycoproteins [62]. During
this time the viral E2 and E1 glycoproteins are engaged with one another as a
heterodimer, and the cleavage of E3 from E2 serves to prime the receptor
complex for future entry events [63]. Also during this time, the viral glycoproteins
are post-translationally modified as they traffic from the ER to the Golgi Complex,
and ultimately, to the cell surface where they will interact with newly formed
nucleocapsid cores leading to the release of mature viral particles.
The ~49kDa alphaviral E2 protein has three ectodomains, termed A, B, C
relative to their position towards the N-terminus, and one subdomain D in close
proximity to domain C [55, 64]. The functions of these domains have been
characterized largely through the use of deletion mutants, or point mutants at the
E1/E2 interface. Domain B is the receptor binding domain, and in the context of
the glycoprotein heterodimer, domains A and B cover the fusion loop of the E1
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protein. The D subdomain interacts extensively with the E3 protein during the
maturation process. In addition, the C-terminal tail of the E2 protein interacts with
a hydrophobic pocket on the capsid protein leading to agreement between the
symmetries of the glycoprotein spikes and the nucleocapsid cores.
The ~52kDa alphaviral E1 protein has three domains, termed I, II, and III
on the basis of their position relative to the N-terminus [55, 65]. The central
domain of E1, domain I, connects to the flanking domains of II and III. Domain II
contains the viral fusion loop peptide, which as described above, is obscured by
the E2 protein until a conformational trigger in response to low pH [66]. Domain
III is largely involved in the structural rearrangements that lead to the fusion of
the virus and host membranes during entry.
In addition to the major glycoproteins described above, the ~6kDa 6K and
~8kDa TF proteins are alternatively produced during translation [67]. The 6k and
TF proteins are encoded by the same gene, but which protein is produced is
determined by a frameshift event at a slip site upstream of the gene [67]. The
roles of these proteins in viral infection have not been well characterized, but
they are known to be important for particle assembly and budding [68].

Alphaviral Arthritis in Mouse Models of Infection
The arthritogenic alphaviruses include Chikungunya, Ross River, Semliki
Forest, Burmah Forest, Mayaro, and Sindbis virus. Each of these viruses have
been demonstrated to be capable of infecting mice and causing pathogenesis,
however the ultimate disease manifestations are dependent on the route of
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inoculation. In order to model arthritic disease in mice, the virus is inoculated
subcutaneously in the rear footpad, where it replicates in skin fibroblasts and
produces high titer viremia. The virus then spreads to the muscle, skeletal
muscle, and joints, resulting in immune infiltration and inflammation in and
around the synovial membranes and connective tissue. This leads to the
development of acute disease which involves biphasic swelling of the inoculated
foot, which peaks around days 3 and 7 post inoculation in adult
immunocompetent mice [69, 70]. While infectious virus is cleared and swelling
goes down approximately 2 weeks post inoculation, viral RNA remains present in
the joint for at least 16 weeks following infection. Severity and presentation of
disease varies with age, as infection in neonatal mice results in lethal
encephalitis (Ross, 1956; Couderc, 2009). The change in lethality and disease
symptoms between young and adult mice is thought to largely be due to the
maturation of the immune system, as the immune system of neonatal mice is not
yet matured [71].
Severity of arthritic disease is thought to be largely mediated by the host
immune response. This is largely supported by studies with CHIKV and RRV
using Rag -/- mice, which are deficient in B-cells and T-cells. In RRV infection,
viral replication and progression of disease mirrored what is seen in WT mice,
leading to the conclusion that innate immune infiltration and cytokine production
are what lead to inflammation in the joint [72]. However, Rag -/- mice infected
with CHIKV show little swelling of the foot during infection, suggesting that the
adaptive immune response plays a much larger role in induction of inflammation
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in CHIKV compared to RRV [73]. In particular, CD4+ T-cells have been shown to
be essential for the development of joint swelling [74]. In addition to T-cells,
macrophages in particular have been linked to progression of disease, as mice
treated with a drug which inhibits production of MCP-1, a major monocyte
chemoattractant, prior to CHIKV infection developed significantly milder disease
and exhibited reduced immune infiltration in the muscle and joint [75]. The
adaptive immune response is known to play a much larger role in viral clearance.
This is supported by a study which showed that Rag -/- mice infected with CHIKV
exhibit persistent viremia and elevated viral burdens compared to wild type
C57BL/6 mice [73]. B-cells are thought to be especially important for clearance of
CHIKV as B-cell deficient mice are unable to clear infection and pre-treatment of
IFNAR -/- mice with anti-CHIK antibodies was found to be sufficient to protect
against lethality [76, 77].

Alphaviral Encephalitis in Mouse Models of SINV Infection
The encephalitic alphaviruses include Venezuelan, Eastern, and Western
Equine Encephalitis Virus. Even though SINV causes arthritis in humans, specific
strains such as AR86 cause lethal encephalitis in mice and thus, SINV serves as
a model for alphaviral neuropathogenesis in mice. Depending on the aim of the
study, the virus is typically inoculated either directly into the brain through
intracranial injection or subcutaneously in the rear footpad. During subcutaneous
infection, the virus quickly replicates in the muscle near the sight of inoculation
and rapidly produces high titer viremia. The virus then targets the central nervous
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system and brain, where it primarily infects neurons in the hippocampus and the
anterior horn of the spinal cord, resulting in large scale inflammation and
encephalitis [78]. At this stage, mice typically develop severe neurological
symptoms, including paralysis of one or multiple limbs, and experience significant
weight loss. Death due to encephalitis occurs between 7-9 days post infection for
5-week old C57BL/6 mice [79]. Severity of disease is dependent on age, as fully
matured mice do not succumb to disease and do not develop severe neurological
symptoms [79, 80]. This age-dependent resistance to SINV infection is believed
to be largely due to the maturation of neurons in the brains and central nervous
system (CNS). This is reflected in tissue culture models of infection, where SINV
infection of undifferentiated neurons resulted in high levels of viral replication and
cell death, while infection of differentiated neurons resulted in low levels of viral
replication and very little to no cell death [81].
The ability of mature neurons to resist SINV infection has been linked to
the expression of a number of proteins, but as of yet, none of have been shown
to confer complete protection from viral infection. Neuron differentiation has been
shown to lead to changes in the expression of antiviral genes, and this is at least
in part due to the increased expression of IRF3 and IRF7 [82]. Interferon
response factors (IRFs) are transcription factors that activate interferon
stimulated gene (ISG) expression in response to interferon (IFN) as well as
induce IFN activation. While both IRF3 and IRF7 likely play important roles in
enhancing antiviral signaling during infection, they are not solely responsible for
restriction of viral replication in mature neurons, as silencing IRF7 expression in
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mature neurons did not restore viral replication to the same levels seen in
immature neurons. In addition to expressing higher levels of antiviral genes,
mature neurons also more readily respond to IFN-γ, which activates the
JAK/STAT signaling pathway and induces the expression of multiple ISGs that
reduce SINV replication [83, 84]. Another important difference between mature
and immature neurons is the expression of apoptosis-modulating proteins. In
particular, Bcl-2 and Bax were found to inhibit SINV-induced apoptosis and their
expression is correlated with survival [85]. Over expression of the apoptotic
proteins Bcl-2 and Bax in weanling mice resulted in lower mortality, suggesting
that they protect neurons associated with survival. However, expression of these
two proteins did not prevent the death of spinal cord motor neurons or hind limb
paralysis, indicating that there are other factors at play.
Viral-induced apoptosis of neurons during infection is thought to be the
main mechanism by which inflammation is induced in the brain, ultimately leading
to encephalitis and the death of the host. SINV, as well as the encephalitic
alphaviruses in general, are thought to induce apoptosis in a number of ways in
the CNS. One is through the fusion of the viral envelope with the host endosomal
membrane can trigger apoptosis by activating sphingomyelinase, leading to the
release of ceramides that induce apoptosis [86]. A second way that SINV may
induce apoptosis in neurons is by decreasing NA+K+-ATPase activity, resulting
in the depolarization of the cell membrane and an influx of toxic levels of Ca2+,
inducing cell lysis [87]. The death of neurons in the brain by viral infection leads
to the release of pro-inflammatory pathogen- and damage-associated molecular
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patterns (PAMPs and DAMPs) as well as glutamate. The release of glutamate in
particular can result in the death of neighboring infected and uninfected neurons.
Excessive activation of the glutamate receptor leads to an influx of Ca2+,
inducing excitotoxic cell death, which releases more PAMPs, DAMPs, and
glutamate, and leads to further bystander death [86, 87].
The release of PAMPs and DAMPs from infected cells as well as the
production of pro-inflammatory cytokines and chemokines results in the
infiltration of immune cells into the brain, namely macrophages and T-cells [88].
In addition to the killing of neurons via direct viral infection, pathogenesis is also
thought to be the result of excessive inflammation caused by the host antiviral
immune response, as initiation of viral clearance and the inflammatory response
correlates with the onset of neurological symptoms [89]. In particular, T-cells are
thought to play a large role in exacerbating inflammation in the brain and their
infiltration into the brain has been linked with fatal encephalomyelitis. This
conclusion comes from studies which showed that mice deficient for αβ T cells
had increased survival compared to wild type mice when infected with
neurovirulent SINV [90, 91]. Therefore, controlling the inflammatory response in
the brain so that viral clearance still occurs without damage to surrounding tissue
is a critical aspect of determining lethality of encephalitic alphaviral disease.
Clearance of virus from the brain occurs in a primarily noncytolytic manner
in order to prevent further damage to neural tissue. This process is largely
mediated by IFNγ produced from T cells as well as antibodies produced by Bcells against the viral glycoproteins [92, 93]. In particular, the B-cell production of
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antibodies which suppress viral infection is important for continued clearance of
virus, as the viral RNA can persist in neurons for years following infection and
has been shown to be capable of reactivating viral replication in mice deficient of
B-cells [84, 94, 95].

Alphaviral Pathogenesis Traits
Using both cellular and animal models of alphaviral disease, several key
determinants of alphaviral pathogenesis have been identified. These virulence
traits span both the viral proteins and the viral RNAs themselves and serve to
both evade the induction of and blunt the efficacy of the innate immune response
to infection. As the alphaviruses are highly sensitive to the effects of the Type-I
IFNs, evading the host innate immune response is critical to alphaviral infection
and pathogenesis. This section will detail the known alphavirus virulence traits.

Virulence Traits of the Nonstructural Proteins
In addition to its roles during alphaviral replication, the nsP1 protein is
known to be important for alphaviral pathogenesis and multiple residues in nsP1
have also been identified as determinants for alphaviral virulence. In particular,
palmitoylation of nsP1 is known to be important for viral pathogenesis as
mutations in nsP1 that prevented palmitoylation were also found to impact
neurovirulence in mice. Specifically, when the palmitoylated residues in nsP1
were mutated to alanine in Semliki Forest Virus (SFV), was found to replicate in
mice and produce viremia but would no longer traffic to the brain and completely
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ablated mortality [96]. Apart from palmitoylation, a set of six mutations in nsP1 of
RRV was found to attenuate viral infection in mice due to reduced viral replication
in specific tissues. More specifically, RRV with these 6 nsP1 mutations was
found to have decreased replication in the skeletal muscle tissue and was more
sensitive to type I IFN [97, 98]. In addition to altered pathogenesis in vivo, the
RRV nsP1 mutant was also shown to have decreased production of noncapped
genomic RNA during viral replication; however, how this may have contributed to
the virus’s attenuation in vivo was unknown [99]. Finally, cleavage of nsP1 from
nsP2 has also been identified to be a major determinant of virulence. The SINV
T538I mutation in nsP1 is known to affect virulence by altering processing of the
nonstructural polyprotein and the virus’s sensitivity to interferon. The substitution
of isoleucine for threonine at position 538 in nsP1 was found to decrease the
speed of polyprotein processing and significantly affect neurovirulence [100,
101]. Mice infected with the SINV that had a threonine at position 538 developed
severe neurological symptoms and high mortality rates. In contrast, those
infected with SINV that had an isoleucine at position 538 only experienced mild
disease and no mortality [102]. This has been attributed to the altered viral
sensitivity to IFN due to the slowed processing of nsP2 preventing it from
inhibiting the JAK-STAT signaling pathway.
nsP2 is known to play several roles apart from its involvement in viral
replication which are critical for alphaviral pathogenesis. This includes inhibiting
the JAK-STAT signaling pathway mentioned above, which is a major means by
which production of antiviral effectors is induced. Binding of IFN to the IFN
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receptor results in the autophosphorylation of the associated kinases JAK1 and
Tyk2 for the type I IFN receptors or JAK1 and JAK2 for the type II IFN receptors.
The kinases in turn then phosphorylate the IFN receptor, which leads to the
recruitment of the STAT proteins. The STAT proteins are then phosphorylated
and released as dimers that then go to the nucleus to activate the transcription of
interferon stimulated genes (ISGs). During alphaviral infection, nsP2 inhibits this
pathway by disrupting the translocation of STAT1 to the nucleus, thus preventing
STAT1 from binding to the DNA and inducing transcription of ISGs [103, 104]. As
stated previously, the inhibition of the JAK-STAT pathway is known to be
important for virulence, as the T538I mutation in nsP1 which alters this activity of
nsP2 results in decreased pathogenesis. In addition to inhibiting the JAK-STAT
pathway, nsP2 is also known to be responsible for host shutoff. In the
arthritogenic alphaviruses, shutoff of host transcription occurs through
translocation of nsP2 to the nucleus, where it induces degradation of RNA
polymerase II subunit RPB1 [45]. nsP2 is also thought to play an important role in
the shutoff of host translation as well, although the exact mechanism is not yet
understood [105]. Host shutoff has been linked to viral cytopathogenicity, as a
P726G mutation in nsP2 which prevents shutoff of host transcription results in
decreased cell death and viral persistence in mammalian cells in vitro [106].
In addition to inhibiting host immunity, transcription, and translation,
modulating the host stress response is also an important aspect of alphaviral
infection. Viral infection can trigger the formation of stress granules within the
host, resulting the in the sequestration of host translation machinery and an
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arrest in both host and viral protein synthesis. Alphaviruses are known to
suppress stress granule formation through the ADP-ribosylhydrolase activity of
nsP3 [47]. By removing ADP-ribose from ADP-ribosylated proteins present in
stress granules, nsP3 is able to disassemble the stress granules that form in
response to infection. This activity of nsP3 is known to be important for efficient
viral replication and thus for pathogenesis as well. Mutations in nsP3 of CHIKV
which abolish hydrolase activity results in virus that is unable to replicate in either
mammalian or mosquito cells. Similarly, reducing the nsP3’s ability to bind ADPribose results in slower viral replication in tissue culture as well as significantly
reduced mortality in 2-day old mice, illustrating the importance of nsP3 ADPribosylhydrolase activity to alphaviral virulence [107].

Virulence Traits of the Structural Proteins
There have also been several virulence determinants identified in the
structural proteins in addition to the nonstructural proteins. In the encephalitic
alphaviruses, capsid is responsible for shutoff of host transcription rather than
nsP2. In contrast to the arthritogenic viruses, shutoff of host transcription by the
encephalitic alphaviruses utilizes capsid, which blocks nucleocytoplasmic
trafficking in the host cell [108]. Similar to what occurs in the arthritogenic
alphaviruses, host shutoff of transcription by the encephalitic alphaviruses is also
associated with cytopathogenicity, as mutations in capsid which prevent host
shutoff also results in decreased cell death [109]. In addition to the capsid
protein, the viral glycoproteins have also been shown to be important for
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virulence, particularly in regard to viral entry. There are multiple residues in the
viral glycoproteins that are known to affect disease severity. In SINV,
development of neurovirulence has been specifically association with mutations
in E1 and E2, which are responsible for membrane fusion and receptor binding
respectively [110]. Mutations in the glycoproteins have also been shown to affect
host range, tissue/cell tropism, cell attachment, and immunogenicity [111-114].

Virulence Traits of the Alphavirus RNAs
In addition to the above protein-based virulence traits, there are multiple
features of the viral RNA that have been characterized as key determinants of
alphaviral virulence. Several contribute to viral infection by preventing detection
of the viral RNA by innate immune sensors. A major way that the host cell
differentiates self from non-self RNA is through the addition of a modified cap
structure to the 5’ end of mRNA. In particular, RIG-I detects RNA in the
cytoplasm which have a 5’ tri- or diphosphate instead of the proper cap structure.
Once RIG-I binds to a noncapped RNA, it interacts with MAVS and starts a
signaling cascade which leads to the induction of type I IFN. In order to avoid
detection by RIG-I, alphaviruses add a type 0 cap to the 5’ ends of the vRNA.
However, this cap differs from the host type 1 cap in that it is not 2’O methylated.
RNA that lack the 2’O methylation of the 5’ cap can be sensed by IFIT1, which
can bind to the RNA and block translation. To avoid detection by IFIT1,
alphaviruses have a stable stem-loop in the 5’UTR which prevents IFIT1 from
binding the vRNA [115]. This structure has been shown to be important for
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virulence in multiple alphaviruses as disruption of the stem-loop with point
mutations in the 5’UTR, especially at nucleotides 3, 5, and 8, results in
attenuated neurovirulence in mice [115-118].
In addition to the viral cap structure and secondary structure in the 5’UTR,
the Opal stop codon between nsP3 and nsP4 is also a determinant for alphaviral
virulence. However, how the Opal stop codon impacts viral pathogenesis
changes depending on the alphavirus. Mutation of the opal stop codon in CHIKV
results in reduced pathogenicity as mice infected with virus where the Opal
codon has been replaced with arginine experience decreased footpad swelling
and reduced inflammation in the joint [119]. In contrast, introduction of the opal
stop codon in SFV lead to significant attenuation of disease in adult mice [120].
There is also some evidence that the importance of the Opal stop codon to
virulence may be dependent on the host. In O’nyong’nyong virus (ONNV), the
presence of the Opal stop codon results in increased viral replication in BHK
cells, but drastically decreased replication in C6/36 mosquito cells [121]. While
the mechanism by which the Opal stop codon impacts virulence has not been
characterized, it is thought to play a role in controlling the amount of nsP4 which
is produced [122].

Noncapped Genomic Alphaviral RNA
While capping of the genome is crucial for viral replication, alphaviral RNA
are not universally capped and the rate at which the vRNA is capped changes
depending on the host. Furthermore, both capped and noncapped vRNA are
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packaged into viral infection, despite the fact that the noncapped genomes
cannot be translated and are essentially noninfectious [99]. During vertebrate
infection, SINV produces and packages approximately four-fold more noncapped
genomic RNA (ncgRNA) than capped genomic RNA (Fig. 1.4A). In contrast,
SINV infection of mosquito produces capped and ncgRNA in approximately equal
parts. Additionally, it is known that different amounts of ncgRNA are produced at
different points during infection. More specifically, in mammalian tissue culture
models of infection, capping efficiency improves and ncgRNA production
decreases as infection progresses (Fig. 1.4B). Regardless, this overwhelming
presence of ncgRNA during viral infection suggests that they play an important
role in alphaviral infection. While the specifics of what the ncgRNA do during
infection are poorly understood, they are known to be important for proper viral
infection. As mentioned in the previous section, a RRV mutant that was
attenuated in mice was found to produce less ncgRNA compared to the WT RRV
[97, 99]. Additionally, the presence of the ncgRNA during infection of mammalian
cells is known to be correlated with the activation of type I interferon [99].
Noncapped genomic RNA are also known to be important for alphaviral infection
of mosquitos, as particles that contained primarily ncgRNA where able to more
efficiently initiate infection in the midgut than those containing capped genomic
RNA [123].
Altogether, these findings suggest that the production of ncgRNA is linked
to alphaviral infection and pathogenesis. However, there has yet to be a study
which directly links ncgRNA production to the virus’s ability to replicate and
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produce disease. This is partially due to the lack of a good system by which
ncgRNA production can be reliably altered for the entire course of infection.
Mackenzie-Liu et al where able to separate particles containing capped RNA
from those containing ncgRNA by density, as the capped RNA correlated with
heavier particles. However, this method only changes the proportion of capped
and ncgRNA present during the initial round of viral infection, as the ratios of
capped to ncgRNA will return to wild type after one round of replication. Thus,
one of the primary goals of this project was to establish a means by which
ncgRNA production could be altered that would last for the entirety of infection.
Characterization of residues in nsP1 that impact vRNA capping have
largely focused on residues that abolish either the methylatransferase or
guanylyltransferase activities of nsP1. Mutation of these residues is lethal to the
virus, making them unsuitable for studying the functions of ncgRNA during viral
infection. However, in 2015 a study by Li et al reported a number of resides in the
nsP1 of VEEV that, when mutated, where capable of decreasing or increasing
cap formation to various degrees. Among them, alanine substitutions at positions
285 and 375 decreased capping efficiency by ~10 and 2 fold respectively
compared to wild type nsP1. Additionally, an alanine substitution at the 354
position increased capping efficiency by ~3.5 fold [124]. This was the first time
that it was shown that it was possible to increase the capping activity of nsP1.
The Y285, N375, and D354 residues in VEEV are very highly conserved among
both the arthritic and encephalitic alphaviruses, making it likely that mutation of
these residues in other alphaviruses will result in a similar effect on capping
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efficiency. Additionally, all three of these residues occur at interesting locations in
the recently described structure of nsP1 (Fig 1.5). The Y285 residue falls within
the capping domain of nsP1 and is known to be involved in binding GTP for
methylation. While the specific location of the N375 residue has not been
resolved, both it and the D354 residue occur in structures that extend out from
the waist of the enzyme and into the pore formed by the nsP1 ring [33]. It is worth
noting that it is currently unknown whether nsP1 is enzymatically active when
forming the ring complex, therefore the location of the N375 and D354 residues
within the structure of nsP1 may differ when nsP1 is active and part of the
replication complex. Overall, the location of these residues in nsP1, their highly
conserved nature, and their ability to affect nsP1 capping efficiency, and
therefore ncgRNA production, made the Y285A, N375A, and D354A mutations in
particular good candidates for determining the importance of ncgRNA to
biological infection.

Rationale
Alphaviruses are known to produce significant quantities of viral genomic RNAs
that lack the canonical viral 5’ cap structure. These noncapped genomic RNA are
known to be packaged into viral particles, despite the fact that the noncapped
genomes cannot be translated and are essentially noninfectious [99].
Furthermore, previous studies suggest that ncgRNA production may be a
determinant of alphaviral pathogenesis [97, 99]. While these findings suggest
that the ncgRNA are important for alphaviral infection, the role that the ncgRNA
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play during viral infection and the development of viral pathogenesis had yet to
be characterized. This led to the hypothesis that the ncgRNAs were critical to
efficient alphaviral infection and the development of pathogenesis. To determine
the role of the ncgRNA during alphaviral infection, we developed a set of nsP1
mutants in SINV that had either increased or decreased RNA capping efficiency,
which would lead to consistently altered ncgRNA production during infection. We
then used these nsP1 capping mutants to characterize the impact of altered
ncgRNA production on viral infection at the molecular level in cellular models of
infection (Chapter 2) as well as on viral pathogenesis using animal models of
infection (Chapter 3). Defining the role of the ncgRNA during alphaviral infection
will not only expand our knowledge by characterizing a novel alphaviral RNA
species, but will also give insight to the development of novel antiviral strategies
with which alphaviral disease may be treated or prevented.
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Figure 1.1. Alphaviral transmission and disease. The natural transmission
cycle of alphaviruses is between an invertebrate vector and a vertebrate host.
Epizootic spillover events can occur that results in the infection of humans. Once
the virus is transmitted from the mosquito vector to a human host, the virus
begins to replicate resulting in high titer viremia as well as febrile illness and
rash. Depending on the alphavirus, the disease then has the potential to develop
into either potentially lethal encephalitis or debilitating arthritis. Examples of
encephalitic alphaviruses include VEEV, WEEV, and EEV, while the arthritogenic
alphaviruses include CHIKV, RRV, SFV, and SINV.

31

Figure 1.2. The alphaviral life cycle. 1) Alphaviral infection begins with the viral
particle binding to receptors on the surface of the host cell and entering via
receptor mediated endocytosis. 2) After entry, the viral envelope fuses with the
endosomal membrane leading to release of the nucleocapsid core, which is then
disassembled to release the viral genome. 3) The viral genome is then translated
to produce the nonstructural proteins, which are processed to form the viral
replicase. The viral replicase then synthesizes the negative strand RNA template
as well as the subgenomic RNA. The subgenomic RNA is then translated to
produce the structural proteins, which include the glycoproteins and capsid. 4)
The glycoproteins are processed in the endoplasmic reticulum and then trafficked
to the cell surface. 5) Capsid associates with the newly synthesized genomic
RNA to form the nucleocapsid core. 6) Newly formed viral particles are released
from the cell via budding.
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Figure 1.3. Alphaviral RNA replication and genetic organization. Translation
of the viral genome produces the nonstructural polyprotein P1234. nsP4 is first
cleaved off and associated with P123 in order to form the complex that is
responsible for synthesizing the minus strand RNA template. P123 is then further
processed into the individual nonstructural proteins nsP1, 2, and 3. The four fully
processed nonstructural proteins then form the replication complex that is
responsible for synthesizing the genomic and subgenomic RNA.
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Figure 1.4. Capped and noncapped genomic RNA are produced during
alphaviral infection. (A) Quantitative assessment of the 5’ terminus of
encapsidated SINV genomic RNAs from particles produced during infection of
mammalian (BHK-21) and mosquito (C6/36) tissue culture cells. (B) Quantitative
assessment of the encapsidated SINV genomic RNAs from particles produced in
34

the mammalian 293HEK tissue culture cell line over time. Data shown are the
means of at least 3 independent replicates, with error bars representing the
standard deviation of the mean. Adapted from Sokoloski et al, 2015 [89].
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Figure 1.5. Structure of nsP1. Amino acid residues of importance are
highlighted as follows: red, Y286; green, D355; blue, N376; pink, capping
domain. PDB-6Z0V.
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CHAPTER 2
INCREASING THE CAPPING EFFICIENCY OF THE SINDBIS VIRUS NSP1
PROTEIN NEGATIVELY AFFECTS VIRAL INFECTION 1

Summary
Alphaviruses are arthropod-borne RNA viruses that are capable of
causing severe disease and are a significant burden to public health. Alphaviral
replication results in the production of both capped and noncapped viral genomic
RNAs, which are packaged into virions during the infections of vertebrate and
invertebrate cells. However, the roles that the noncapped genomic RNAs
(ncgRNAs) play during alphaviral infection have yet to be exhaustively
characterized. Here, the importance of the ncgRNAs to alphaviral infection was
assessed by using mutants of the nsP1 protein of Sindbis virus (SINV), which
altered the synthesis of the ncgRNAs during infection by modulating the protein’s
capping efficiency. Specifically, point mutants at residues Y286A and N376A
decreased capping efficiency, while a point mutant at D355A increased the
capping efficiency of the SINV genomic RNA during genuine viral infection. Viral
growth kinetics were significantly reduced for the D355A mutant relative to wild

This chapter is adapted from work published in mBio, 2018, Volume 9, Issue 6 with the same
title under a Creative Commons Attribution (CC BY) license 125. LaPointe, A.T., et al., The
Identification and Characterization of Sindbis Virus RNA:Host Protein Interactions. J Virol, 2018.
1
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type infection, whereas the Y286A and N376A mutants showed modest
decreases in growth kinetics. Overall genomic translation and nonstructural
protein accumulation was found to correlate with increases and decreases in
capping efficiency. However, genomic, minus strand, and subgenomic viral RNA
synthesis was largely unaffected by the modulation of alphaviral capping activity.
In addition, translation of the subgenomic vRNA was found to be unimpacted by
changes in capping efficiency. The mechanism by which decreased presence of
ncgRNAs reduced viral growth kinetics was through the impaired production of
viral particles. Collectively, these data illustrate the importance of ncgRNAs to
viral infection and suggests that they play in integral role in the production of viral
progeny.

Introduction
Alphaviruses are positive sense, single-stranded RNA viruses which are
capable of being transmitted between sylvatic vertebrate reservoir hosts and
competent mosquito vectors in an enzootic cycle. During epizootic events, these
viruses are capable of causing severe disease and are broadly categorized into
two groups based on symptomology. Disease caused by the encephalitic
alphaviruses, such as Venezuelan Equine Encephalitis virus, are characterized
by neurological symptoms and are capable of causing severe encephalitis, which
may result in the death of the vertebrate host [11, 12]. In contrast, the
arthritogenic alphaviruses, such as Sindbis virus (SINV), Ross River virus (RRV),
and Chikungunya (CHIKV), cause disease ranging in severity from mild febrile
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illness to debilitating polyarthritis, which may persist for several months to years
past the acute phase of infection [3, 5, 126-128]. Despite the burden to public
health posed by the alphaviruses, there are currently no effective and safe
antiviral treatments for alphaviral disease.
During alphaviral infection, three viral RNA species are produced: the
genomic strand, which encodes the nonstructural polyprotein, which is processed
proteolytically to form the replication machinery; a minus strand RNA template;
and a subgenomic RNA, which encodes the structural proteins. The positive
sense alphaviral RNAs (vRNAs), namely the genomic and subgenomic vRNAs,
have a type-0 cap structure co-transcriptionally added to their 5’ ends during
RNA synthesis in order to protect the 5’ end of the transcript and to facilitate
translation after entry to the host cell [129-131]. The addition of the 5’ cap
structure to the positive sense vRNAs is a multistep process involving at least
two alphaviral nonstructural proteins. Briefly, the methyltransferase domain of the
alphaviral nsP1 protein catalyzes the addition of a methyl group from Sandenosylmethionine to a GTP molecule, forming a covalent m 7GMP-nsP1
intermediate [132]. Following the removal of the 5’ γ-phosphate on the nascent
vRNA molecule by nsP2, the m7GMP moiety is then transferred to the vRNA
molecule by the guanylyltransferase activities of nsP1, resulting in the formation
of the type-0 cap structure,

7meGpppA

[40, 133]. Importantly, biochemical studies

of alphaviral nsP1 proteins have found that both the methyltransferase and
guanylyltransferase activity of nsP1 can be altered either negatively or positively
via point mutations in vitro [35, 124, 134].
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The presence of the type-0 cap structure on the alphaviral genomic and
subgenomic vRNAs were first observed by paper electrophoresis, or thin-layer
chromatography, of metabolically labeled vRNAs that were chemically and
enzymatically degraded [129, 130, 135]. These studies further identified the
sequences of the 5’ termini of the alphaviral genomic and subgenomic vRNAs,
which provided the first evidence for independent promoter initiation for the two
positive-sense vRNA species [130]. While these studies were able to identify the
presence of the 5’ type-0 cap structure, they were, by the nature of their design
and technological limitations, unable to determine the relative frequency with
which the positive sense vRNAs were capped.
Recently, we reported findings that indicated that the alphaviral genomic
vRNAs are not ubiquitously capped, and that a significant proportion of the
genomic vRNAs produced during SINV and RRV infection lack the 5’ type-0 cap
structure [99]. Furthermore, analyses of infectious and noninfectious viral
particles demonstrated that both the capped and noncapped genomic vRNAs are
packaged into viral particles throughout the course of infection. Through the use
of tissue culture models of alphaviral infection, the presence of the noncapped
vRNAs were found to correlate with the activation of a type-I IFN response.
Moreover, an attenuated RRV mutant was found to produce fewer noncapped
genomic RNAs relative to wild type virulent RRV [97, 99]. Collectively, these data
were highly suggestive of an important biological role for the noncapped genomic
vRNAs during infection; however, the precise functions of the noncapped
genomic vRNAs during infection remained unknown.
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The goal of this study was to determine the importance of noncapped
vRNAs to SINV infection of tissue culture cells. Here, we show that the capping
activity of SINV nsP1 is capable of being modulated, both positively and
negatively, via the mutation of specific residues within the Iceberg Domain, a
structurally organized domain of cryptic function that is conserved amongst many
viral capping enzymes (12). In addition, SINV infection was determined to be
more detrimentally impacted by increasing the capping efficiency of SINV nsP1,
rather than by decreasing efficiency. Specifically, increasing the rate of alphaviral
capping negatively impacts viral growth kinetics by negatively affecting viral
particle production. Collectively, our findings indicate that the noncapped vRNAs
do play an important role during viral infection, and that decreasing the presence
of noncapped vRNA impacts the viral life cycle at a fundamental level.

Materials and Methods

Tissue Culture Cells
Baby hamster kidney 21 (BHK-21) fibroblast cells (a gift from R.W. Hardy,
Indiana University- Bloomington) were maintained in Minimal Essential Media
(MEM, Cellgro) containing 10% fetal bovine serum (FBS, Atlanta Biologicals), 1%
antibiotic-antimycotic solution (Cellgro), 1% nonessential amino acids (Cellgro),
and 1% L-glutamine (Cellgro). Cells were cultured at 37 °C and at 5% CO2 in a
humidified incubator. Low passage stocks were maintained via regular passaging
using standard subculturing techniques.
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Generation of SINV Capping Mutants
The SINV nsP1 mutants used in this study were generated either by site
directed mutagenesis, or Gibson assembly reactions. Particularly, the SINV p389
Y286A and D355A mutants were generated via site-directed mutagenesis
according to the instructions for Q5 site-directed mutagenesis kit (NEB). To this
end, the parental wild type strain consisting of the p389 SINV nsP3-GFP reporter
strain was PCR amplified with high fidelity Q5 DNA polymerase using primer sets
that incorporated the indicated alanine substitutions, individually. Due to technical
limitations that prevented the successful use of site-directed mutagenesis, the
N376A mutant was generated by Gibson assembly via the Gibson Ultra kit (SGI)
through the use of restriction digested p389 cDNA plasmid and a synthetic DNA
fragment, according to the manufacturers’ instructions. SINV nanoluciferase
reporters mutants, similar to those previously described, were generated by
either site-directed mutagenesis, or by conventional restriction enzyme cloning
schemes which swapped the GFP coding region of the existing p389 site
mutants with a Nanoluciferase coding region in a modular fashion [99].
In all cases, individual mutants were verified by whole genome
sequencing before proceeding to subsequent analyses. Full genome sequences
are available upon request. Highly similar phenotypes were observed for any
given mutant in all virus backgrounds evaluated.

Production of SINV Wild Type and Mutant Virus Stocks
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Wild type, Y286A, D355A, and N376A SINV p389 (a derivative of the
Toto1101 strain containing GFP in frame with nsP3 [136]), as well as SINV
pToto1101-nanoluc (a derivative of the Toto1101 strain containing nanoluciferase
in frame with nsP3 [99]), were prepared by electroporation as previously
described [125, 137]. Briefly, 2.8x106 BHK-21 cells were electroporated with
10μg of in vitro transcribed RNA using a single pulse at 1.5kV, 25mA, and
200Ohms from a Gene Pulser Xcell system (BioRad) as previously described
[125]. Cells were then incubated at normal incubation conditions until cytopathic
effect became apparent, at which point the supernatant was collected and
clarified by centrifugation at 8,000xg for 10min at 4oC. The clarified supernatant
was then aliquoted into small-volume stocks, which were then stored at -80 oC for
later use.

Analysis of Viral Growth Kinetics
To determine if mutation of the SINV nsp1 protein negatively affected
infection, the viral growth kinetics of each of the individual strains described
above were assayed in tissue culture models of infection. Essentially, BHK-21
cells were seeded in a 24-well plate and incubated under normal conditions.
Once cell monolayers were 80-90% confluent, they were infected with either the
wild-type parental virus, or the individual capping mutant viruses, at an MOI of 5
infectious units (IU) per cell. After a 1hr adsorption period, the inoculum was
removed and the cells were washed twice with 1x PBS to remove unbound viral
particles. Whole media was added, and the cells were incubated at 37 ⁰C in a
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humidified incubator in the presence of 5% CO2. At the indicated times post
infection, tissue culture supernatants were harvested (and the media replaced),
and viral titer was determined via plaque assay.

Quantification of Infectious Virus by Plaque Assay
Standard virological plaque assays were used to determine the infectious
titer of all viral samples produced during these studies. Briefly, BHK-21 cells were
seeded in a 24-well plate and incubated under normal conditions. Once the cell
monolayers were 80-90% confluent, they were inoculated with 10-fold serial
dilutions of virus-containing samples. After a 1hr adsorption period, cells were
overlaid with a solution of 0.5% Avicel (FMC Corporation) in 1x media for 2830hrs [138]. The monolayers were fixed with formaldehyde solution (3.8%
formaldehyde in 1xPBS) for a period of no less than one hour. Plaques were
visualized via staining with crystal violet after removal of the overlay and
quantified by manual counting.

XRN1 Protection Assay/ RppH Assay
Viral genomic RNAs were extracted from purified viral particles harvested
at 24hpi. After extraction, the RNA samples were subjected to enzymatic
degradation via the 5’3’ exonuclease XRN-1, which is capable of degrading 5’
monophosphate and RNAs in vitro, but is unable to effectively degrade RNA
substrates that are 5’ capped [139, 140]. Briefly, equivalent amounts of viral
genomic RNAs were incubated in the presence of 0.25 units of XRN-1 in a final
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volume of 20μl for a period of 5 minutes at 37° prior to being quenched via the
addition of High Salt Column Buffer (25mM Tris-HCl, pH 7.6 / 400mM NaCl /
0.1% w/v Sodium Dodecyl Sulfate (SDS). After the termination of the reaction,
the RNAs were purified via phenol:chloroform extraction and ethanol precipitation
with linear acrylamide carrier. The resulting precipitate was resuspended and
utilized as the substrate for the synthesis of cDNA via ProtoScript II reverse
transcriptase (NEB). The resulting cDNAs were quantified via qPCR of an
amplicon located in the nsP1 region, as described below, to determine the
sensitivity of a sample relative to wild type viral genomic vRNAs [125, 141].
To confirm that the nature of the 5’ end, in particular the presence of a 5’
cap structure, was responsible for the differences in XRN-1 sensitivity the
extracted RNAs were co-incubated with XRN-1 in the presence of the decapping
enzyme RppH [99, 142, 143]. To this end, the above reactions were
supplemented with 1.25 units of RppH and processed as described above.

Metabolic Labeling of Protein Synthesis
To determine the rates of host and viral during infection, BHK-21 cells
were seeded in a 12-well tissue culture dish and grown to 80-90% confluence
prior to being infected with either wild type parental virus, or one of the individual
capping mutant viruses at an MOI of 10 IU/cell. After a 1hr adsorption period,
fresh media was added to each well, and the cells were incubated under their
normal incubation conditions. Thirty minutes before the indicated times post
infection, the media was removed and replaced with methionine- and cysteine-
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free DMEM (Cellgro) to starve the cells of methionine. After a 30 minute
incubation period, the starvation media was removed and replaced with
methionine- and cysteine-free DMEM supplemented with 50μM Lazidohomoalanine (L-AHA), a methionine analogue [144, 145]. After 2hrs, the
labeling media was removed, the cells were washed with 1x PBS, and then
harvested with RIPA buffer (50mM Tris-HCl, pH 7.5 / 150mM NaCl / 1% v/v
Nonidet P-40 (NP-40) / 0.5% w/v SDS / 0.05% w/v Sodium Deoxycolate / 1mM
EDTA). Cell lysates were labelled with DIBO-Alexa 648 (Invitrogen) at a final
concentration of 5μM and incubated at room temperature in the dark for at least 1
hour. The labeled lysates were then loaded onto a 12% SDS-PAGE gel, and the
proteins were separated by electrophoresis. Fluorescence was then imaged
using a Pharos FX Plus Molecular Imager (BioRad), and densitometry of
individual protein species was used to quantify viral and host protein expression.

Western Blot Detection of SINV nsP2 Protein Expression
Whole cell lysates were generated from BHK-21 cells infected with either
wild type, or individual SINV nsP1 capping mutant viruses by resuspension in
RIPA buffer at 12 and 16hpi. Equivalent amounts of protein were loaded onto
10% acrylamide gels, and the individual protein species were resolved using
standard SDS-PAGE practices. After sufficient resolution of the protein species,
the proteins were transferred to PVDF membranes, which were rinsed in
methanol and thoroughly dried after transfer. After drying the blots were probed
with anti-SINV nsP2 polyclonal sera (a gift from R.W. Hardy at Indiana
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University- Bloomington), or anti-Actin (clone mAbGEa, ThermoFisher Scientific)
antibodies diluted in 1xPBS supplemented with 1.0% v/v Tween (PBST) for a
period of at least one hour at 25ºC under gentle rocking. The blots were washed
three times with 1xPBST, and probed with fluorescent anti-rabbit (A32732,
ThermoFisher Scientific) and anti-mouse secondary (A32723, ThermoFisher
Scientific) antibodies. Protein detection was achieved using a Pharos FX Plus
Molecular Imager (BioRad), and densitometry of individual protein species was
used to quantify viral and protein expression.

qRT-PCR Detection of SINV vRNAs
The quantitative detection of the SINV vRNAs was accomplished as
previously described, with minor modifications [137]. Briefly, to quantify the SINV
genomic, subgenomic, and negative sense vRNAs, BHK-21 cells were infected
at an MOI of 5 IU/cell and cells were harvested at 2, 4, and 8hpi via the addition
of Ribozol (VWR). Total RNA was then isolated via extraction, and 1μg was
reverse transcribed using Protoscript II Reverse Transcriptase (NEB) and a
cocktail of specific RT primers based on the intended amplification targets. To
detect the positive-sense RNA species the RT primer cocktail consisted of nsP1,
E1, and 18S reverse primers; and to detect the minus strand the RT cocktail
consisted of nsP1 forward and 18S reverse primers. The individual vRNA
species were detected via TaqMan probes using the following primer sets: SINV
nsP1 F 5’-AAGGATCTCCGGACCGTA-3’, SINV nsP1 R 5’AACATGAACTGGGTGGTGTCGAAG-3’; SINV E1 F 5’-
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TCAGATGCACCACTGGTCTCAACA-3’, SINV E1 R 5’ATTGACCTTCGCGGTCGGATACAT-3’; Mammalian 18S F 5’CGCGGTTCTATTTTGTTGGT-3’, Mammalian 18S R 5’AGTCGGCATCGTTTATGGTC-3’. The sequences of the TaqMan detection
probes are as follows: SINV nsP1 Probe 5’ACCATCGCTCTGCTTTCACAACGA-3’, SINV E1 Probe 5’ACTTATTCAGCAGACTTCGGCGGG-3’, and Mammalian 18S Probe 5’AAGACGGACCAGAGCGAAAGCAT-3’.
To quantify the total number of viral particles present in a sample, BHK21 cells were infected at an MOI of 5 IU/cell and supernatant was collected at
24hpi. As previously described, 5uL of supernatant was reverse transcribed
[137]. Reverse transcription and qPCR reactions were performed identical to
those above with the exception of the mammalian 18S primer and probes not
being used. Absolute quantities of viral genomic RNAs were determined via the
use of a standard curve of known concentration. To determine the amount of
subgenomic vRNA present, the absolute quantities of RNA detected with the
nsP1 primer set were subtracted from that detected with the E1 primer set, as the
E1 primer set will detect both the genomic and subgenomic RNAs, but the nsP1
primer set will only detect the genomic RNA.

Cell Viability Assay
To determine the effect of SINV infection on cell viability, BHK-21 cells
were seeded in a 96-well plate and were infected with the wild type parental virus
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or the individual capping mutant viruses at an MOI of 10 IU/cell. After a 1hr
adsorption period, whole medium was added and the cells were incubated under
normal incubation conditions for the described times. Afterwards, the cells
washed with 1x PBS and a solution of 1/6 th CellTiter 96 AQueous One Solution
Reagent (Promega) in 1x PBS was added to each well. The cells were then
allowed to incubate at 37oC and 5% CO2 for 2hrs. Absorbance at 490nm was
then recorded using a Synergy H1 microplate reader (BioTek).

Quantification of Viral Gene Expression via Nanoluciferase Assays
To quantify genomic translation during infection, BHK-21 cells were
infected at an MOI of 5 IU/cell with the wild type parental virus or the individual
capping mutants containing the nanoluciferase gene within the nsP3 protein [99].
After a 1hr adsorption period on ice, the inoculum was removed and the medium
was replaced with pre-warmed whole medium. The infected cells were incubated
under normal conditions, and at the indicated times post-infection, the medium
was removed and the tissue culture cells were washed with 1x PBS. The cells
were then harvested into a crude lysate by the addition of 1x PBS supplemented
with 0.5% (v/v) Triton X-100. The lysate was transferred to a microfuge tube and
frozen until the completion of the experimental time course. The samples were
thawed and clarified by centrifugation at 16,000Xg for 5 minutes, and equal cell
volumes of the nanoluciferase samples were processed using the Nano-Glo
nanoluciferase assay system (Promega) according to the manufacturer’s
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instructions. Luminescence was then recorded using a Synergy H1 microplate
reader (BioTek).

Statistical Analysis
The quantitative data reported in this study are the means of a minimum of
three independent biological replicates, unless specifically noted otherwise. The
growth curve data presented in Fig. 2.2 were statistically assessed using an area
under the curve approach to determine differences in viral growth kinetics
throughout the course of the assay. The statistical analysis of comparative
samples was performed using variable bootstrapping where appropriate, as
previously described [137]. The error bars indicate the standard deviation of the
mean. The P values associated with individual quantitative data sets are the
result of Student’s t test for the corresponding quantitative data.

Results
SINV vRNA Capping Can be Modulated by Point Mutations in the nsP1
Protein
As described above, we recently reported that a significant number of
SINV genomic vRNAs produced during infection lack the type-0 5’ cap structure.
Despite being noninfectious, the noncapped viral genomic RNAs (ncgRNAs) are
produced in a temporally dependent manner and are packaged into viral particles
throughout the course of infection [99]. Given the evolutionary conservation of
the production of the ncgRNAs during alphaviral infection, we hypothesized that
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they must be biologically important to viral infection. This led us to question how
modulating capping activity, which would alter the production of capped viral
genomic RNAs and ncgRNAs, impacts viral infection. In order to determine the
biological importance of the ncgRNAs during viral infection, we modulated the
methyltransferase and guanylyltransferase activities of the alphaviral nsP1
protein to generate mutant SINV strains with either increased or decreased rates
of viral capping. These mutations were based on previous work done in VEEV by
Li et al. (2015), where alanine substitutions at specific residues affected the nsP1
protein’s methyltransferase and guanylyltransferase activities, as well as cap
formation as a whole. Specifically, the previous study found that alanine
substitutions at Y286 and N376 decreased RNA capping efficiency, although to
different extents, whereas an alanine substitution at D355 increased RNA cap
formation. All three residues are highly conserved across multiple alphaviruses,
including the model alphavirus SINV (Fig. 2.1A). Modeling of the SINV nsP1
protein using ITASSER indicates that residues D355 and N376 are likely close to
one another, in parallel alpha helices proximal to the catalytic site within the
Iceberg Domain (Fig. 2.1B)[146]. Nonetheless, Y286 is located at a distal site far
from the putative active sites, as identified by prior mutational analyses [35, 132,
133]. Admittedly, the ITASSER predicted structure is unlikely to be a wholly
accurate representation of the true structure of the SINV nsP1 protein. Despite
the inherent inaccuracy of protein folding prediction algorithms in the absence of
a closely related crystal structure, secondary and tertiary structural elements
reminiscent of methyltransferase and guanylyltransferase enzymes may be
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detected, including a Rossmann fold-like structure surrounding the key residues
involved in methyltransferase activity [35, 147]. In addition, the overall
arrangement of the Core Region and Iceberg Domains are largely intact, and the
known membrane anchoring domains face outward from the globular body of the
protein [147]. The differential ability of the Y286, D355, and N376 to affect VEEV
nsP1 capping activity as well as their locations in highly conserved domains,
which play integral roles in cap formation, made them strong candidates for
testing how modulating the capping activity of nsP1 affects SINV infection.
In order to verify that the SINV nsP1 mutations altered the rate of vRNA
capping, we assessed what proportion of viral particles contained capped RNA
genomes. We have shown previously that both capped genomic RNAs and
ncgRNAs are packaged and released during viral infection [99]. Thus, knowing
what proportion of capped viral RNA is being packaged into viral particles gives
insight into the general capping efficiency of nsP1 during viral infection. To this
end, the comparative assessment of viral capping was accomplished by
comparing the relative sensitivity of the mutants to RNAse degradation using
XRN-1, a 5’-3’ exoribonuclease which preferentially degrades RNAs lacking a
protective 5’ cap structure, in particular 5’ monophosphate RNAs [139, 140]. By
measuring the amount of RNA resistant to XRN-1 degradation, we were able to
determine what relative proportion of the total input RNA was capped relative to
wild type SINV, as the predominant noncapped 5’ end was previously determined
to be a 5’ monophosphate [99]. As shown in Figure 2.1C, both SINV N376A and
SINV Y286A had significantly lower proportions of XRN-1 resistant genomic
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RNAs compared to WT, with SINV Y286A having approximately 25% less XRN-1
resistant RNA compared to WT, and SINV N376A having approximately 75%
less XRN-1 resistant RNA. In contrast, and as expected from the previous study
by Li et al. (2015), SINV D355A was found to have a significantly greater
proportion of XRN1-resistant RNA, with a mean approximately four-fold greater
than what was observed for WT SINV. To confirm that the observed resistance of
the SINV D355A genomic RNAs was due to a cap structure, the genomic RNAs
were subjected to XRN-1 nuclease treatment in the presence of an established
decapping enzyme [99, 142, 143]. As shown in Figure 2.1D, enzymatic removal
of the 5’ cap structure eliminated the resistance of the D355A derived genomic
RNAs to XRN-1 treatment, resulting in XRN-1 resistances comparable to WT
SINV.
From these data, we were able to conclude that the point mutations
engineered into the SINV nsP1 protein can indeed alter capping activity, both
negatively, in the case of Y286A and N376A; and positively, as with D355A.
Therefore, the individual nsP1 mutants can be used to assess the impact of the
ncgRNAs by modulating the capping activity of nsP1 in tissue culture models of
infection in a controlled manner.

Increased Capping Decreases SINV Growth Kinetics in Mammalian Cells
While the effects of synonymous point mutations on nsP1 capping
efficiency have been previously characterized for VEEV at an enzymatic level
[124], the effects of modulating capping activity on viral infection as a whole has
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not yet been studied in detail. Given the molecular function of the 5’ cap
structure, one could expect that the SINV nsP1 mutants that decreased vRNA
capping would show impaired viral growth kinetics relative to wild type virus.
Likewise, if the ncgRNAs were truly nonfunctional, a mutant that increased
capping would show enhanced viral growth kinetics in regards to wild type
infection. As demonstrated by the data presented in Fig. 2.2A, decreasing SINV
capping modestly decreased viral growth kinetics, as observed for the SINV
Y286A and SINV N376A mutants. However, the SINV D355A mutant, which
increased vRNA capping relative to WT, exhibited significantly decreased titers
over the course of infection (Fig. 2.2A). In addition to a 2-log decrease in viral
titer, the SINV D355A mutant produced plaques approximately half the size of
those produced by wild type SINV (Fig. 2.2B and 2.2C). Despite not showing
significantly decreased viral growth kinetics, both the SINV Y286A and SINV
N376A mutants also exhibited a small plaque phenotype, albeit not to the same
extent as the SINV D355A mutant. In addition, all three capping mutants were
found to have decreased induction of cell death compared to WT SINV (Fig.
2.2D).
Collectively, these data indicate that changing the efficiency of vRNA
capping negatively impacted viral growth kinetics, illustrating that a step in the
viral life cycle has been detrimentally affected. Furthermore, the viral growth
kinetics data suggests that SINV is more sensitive to increased vRNA capping
efficiency than it is to decreased capping efficiency. Thus, the ncgRNAs
produced during infection are indeed biologically important. Nevertheless,
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despite the clear negative impact to viral infection, the precise nature of the
molecular consequences of increased vRNA capping and decreased presence of
ncgRNAs cannot be determined from these data alone. As such, the viral gene
expression and vRNA synthesis profiles of each of the SINV nsP1 mutants were
next assessed to determine if they were negatively affected by modulation of
vRNA capping.

Translation of the SINV Genomic RNA Correlates with Capping Efficiency
For the majority of mRNAs, a key factor for determining whether or not an
mRNA is translated is the presence of a functional 5’ cap structure [148-150].
Therefore, changing the ncgRNAs to capped genomic RNAs or vice versa by
altering viral capping efficiency should impact the amount of protein being
produced by viral RNA during infection. To investigate the effect(s) that
modulating nsP1 capping efficiency has on viral gene expression, a SINV
reporter, which contained the open reading frame of nanoluciferase in frame with
the nsP3 nonstructural protein, was used to measure viral genomic RNA
translation throughout infection (Fig. 2.3A) [99]. Nanoluciferase expression was
measured at regular intervals over the course of viral infection (Fig. 2.3B). As
expected, the SINV D355A mutant, which increased capping relative to wild type,
exhibited increased genomic vRNA translation compared to WT SINV for every
time point measured (Fig. 2.3C). Similarly, SINV N376A, which decreased
capping relative to wild type, showed decreased translation (Fig. 2.3C).
Curiously, the SINV Y286A mutant showed differential nanoluciferase expression
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during infection, with translation being slightly increased very early during
infection, decreased at 8hpi, and similar to wild type at later times post infection.
While the SINV nanoluciferase reporter virus allows for the accurate
quantification of viral gene expression during infection, it does not measure the
sum accumulation of the nonstructural proteins. To measure the relative
accumulations of the viral nonstructural proteins, the levels of SINV nsP2 protein
were assessed via Western blotting at 8, 12 and 16hpi. As shown in Fig. 2.4A
and quantified in. Fig 2.4B, at 8hpi the accumulation of the SINV nsP2 proteins
between wild type SINV, SINV D355A, and SINV N376A differed to a statistically
significant extent. The abundance of nsP2 was increased ~2.5-fold during SINV
D355A infection, relative to wild type SINV. In contrast, nsP2 levels during SINV
N376A infections were decreased ~2-fold relative to wild type SINV infections.
The SINV Y86A mutant was more or less equivalent to wild type nsP2 levels.
Similar trends were observed at later times during infection. As depicted in Figs.
2.4C and 2.4D, at 12hpi the SINV nsP2 levels were statistically increased relative
to wild type infection; however, given the low magnitude of effect, these
differences are unlikely to be biologically significant. In contrast, at 16hpi SINV
nsP2 levels were increased to an extent that is likely biologically meaningful (Figs
2.4E and 2.4F).
Overall, the levels of genomic translation for the SINV nsP1 mutants nicely
reflect their relative differences in capping efficiency, with increased vRNA
capping resulting in increased translation of the nonstructural proteins, and
decreased vRNA capping resulting in decreased translation at 8hpi. These data
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are consistent with the conversion of the ncgRNAs to translationally competent
capped genomic vRNAs. Furthermore, western blotting confirmed the differences
in translational activity detected during SINV nanoluciferase reporter infections.
Taken together, the nanoluciferase and western blot data indicate that the
translation of the genomic vRNAs continues during infection with SINV D355A
beyond what is observed for wild type SINV. Nonetheless, the biological
differences in translational activity observed between the SINV D355A mutant
and its respective parental wild type strain fail to explain the approximately 200fold reduction in viral titer.

Modulating SINV Capping Does Not Alter Overall RNA Synthesis or
Accumulation
Since differences in viral gene expression failed to outright explain the
observed decreased viral titers associated with the SINV D355A mutant, we next
sought to identify if vRNA synthesis was impaired as a result of nsP1 mutation.
To determine what impact altering viral capping efficiency has on vRNA
synthesis, the genomic, subgenomic, and minus strand vRNAs were
quantitatively assessed at 2, 4, and 8 hours post infection via qRT-PCR. At 2hpi,
the SINV D355A mutant, which has increased vRNA capping relative to wild type
SINV, produced slightly more SINV genomic and subgenomic RNAs; whereas
the SINV N376A mutant, which exhibits decreased vRNA capping, produced
slightly fewer genomic and subgenomic RNAs (Fig. 2.5A). In general, the
differences in the amount of genomic and subgenomic RNAs being produced by
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these two capping mutants is reflective of the differences observed in the
synthesis of their replication machinery (Figs. 2.3 and 2.4). At 4hpi, all three
SINV nsP1 mutants show a statistically significant deficit in the amount of
subgenomic RNA present (Fig. 2.5B). Nonetheless, these deficits are unlikely to
be biologically meaningful due to their overall magnitude of effect relative to wild
type SINV. By 8hpi however, all three capping mutants show similar levels of all
three RNA species compared to WT, with the exception of N376A, which had
less minus strand template compared to WT (Fig. 2.5C).
Altogether, these data demonstrate that altering the capping activity of
nsP1 may have impacts on RNA synthesis very early during viral infection, but
that these differences become muted as infection progresses. Importantly, these
data indicate that vRNA synthesis on the whole has not been disrupted,
precluding the possibility that the point mutations made in nsP1 have disrupted
the function of the other nonstructural proteins. Moreover, similar to that
described above regarding viral gene expression in the previous section, the ~2log reduction in viral growth kinetics observed for the SINV D355A mutant is not
due to decreased vRNA accumulation or defective vRNA synthesis.

Translation of the SINV Subgenomic RNA is Largely Unaffected by Viral
Capping
Given that neither the differences in nonstructural gene expression or
vRNA synthesis were capable of explaining the negative impact of the SINV
nsP1 D355A mutation, we next sought to determine if the function of the
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subgenomic vRNAs were impacted. As both the genomic and subgenomic
vRNAs are capped by nsP1, it was hypothesized that mutations which increased
capping of the genomic vRNAs might impact subgenomic vRNA function. As
such, it could be expected that these vRNAs would exhibit similar responses to
altered capping in terms of translation. In order to determine whether translation
of the subgenomic vRNAs were impacted similarly to the genomic vRNAs, the
amount of protein produced late during infection was measured using metabolic
labeling (Fig. 2.6A). Curiously, both the SINV D355A and SINV N376A mutants
exhibited a modest decrease in viral capsid production (Fig. 2.6B). In addition,
none of the SINV nsP1 mutants exhibited differences in regards to the shutoff of
host translation, a hallmark of alphaviral infection as reviewed in [151], as
evidenced by the labeling of the cellular Actin protein, relative to WT SINV (Fig.
2.6C). Interestingly, however, the ongoing synthesis of a high molecular weight
protein consistent with the nonstructural polyprotein was reproducibly detected
during the metabolic labeling of SINV D355A mutant infections.
Collectively, these data indicate that changes in capping efficiency of the
genome may either not lead to equivalent changes in capping of the subgenomic
vRNA; or alternatively, that SINV, and likely other alphaviruses, regulate the
translation of the structural proteins differently than the nonstructural proteins
[152]. Regardless, these data suggest that subgenomic translation and host
translational shutoff are not impacted to a biologically significant degree by
modulating the efficiency of vRNA capping, and thus are not responsible for the
decreased viral titer associated with increased capping efficiency.
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Increasing SINV Capping Decreases Viral Particle Production
Given that the molecular characterizations of the SINV nsP1 mutants had
so far failed to identify the molecular defect leading to decreased viral growth
kinetics, we expanded our analyses beyond the lifecycle events most obviously
affected by the 5’ cap structure. Since vRNA synthesis and viral gene expression
were unaffected, we next sought to determine whether viral particle assembly
was negatively impacted by increasing the capping efficiency of the SINV nsP1
protein.
To determine whether increasing capping efficiency affected viral particle
production, we quantified the total number of particles produced by each mutant
as well as wild type SINV after 24hrs of infection. Similar to what was observed
during the kinetic analyses of viral infection, increased vRNA capping was
associated with the production of significantly fewer particles, with the SINV
D355A mutant producing ~25-fold fewer particles (as measured by genome
equivalents per ml) than wild type SINV (Fig. 2.7A). In contrast, particle
production was largely unaffected during infections of the SINV Y286A and SINV
N376A mutants, which decreased vRNA capping.
The point mutants utilized in this study are located within, or closely
adjacent to, the SINV packaging signal [153]. Previous characterizations of the
alphaviral packaging signals have indicated the importance of stem-loop
structures which contained a guanosine triplet in the loop region. Mutational
analyses of the alphaviral packaging elements determined that mutation of the
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guanosine triplets, or deletion of the packaging element altogether, significantly
reduced viral titer due to nonselective particle assembly leading to the production
of alphaviral particles containing the subgenomic vRNAs [153]. Further
experiments defined that a minimum of two guanosine triplet stem loops was
sufficient to impart wild type particle production with selectivity for the genomic
RNA. Even though none of the point mutants used in this study impact either the
guanosine triplets, or the general secondary structures (as predicted by in silico
analysis), the potential for the inhibition of assembly by a non-capping
mechanism existed, warranting further assessment of particle production during
SINV nsP1 mutant infections. As mentioned earlier, disruption of the alphaviral
packaging signal leads to the production of viral particles containing
predominantly subgenomic RNAs [153]. As shown in Fig. 2.7B, quantitative
determinations to identify which specific vRNAs were packaged into wild type
and SINV nsP1 mutant viral particles indicated no aberrant packaging of the
SINV subgenomic RNA, consistent with an intact functional packaging signal.
The high degree of similarity between the relative magnitude of effect
regarding decreased viral titer and viral particle production during SINV D355A
infection indicates that particle assembly, and not the slight perturbations in
vRNA synthesis or structural gene expression, is primarily responsible for
decreased viral growth kinetics. Importantly, these data suggest that SINV, on
the whole, is much more tolerant of mutations which decrease capping efficiency
than those that increase capping efficiency, and that by increasing the capped to
noncapped viral RNA ratio, viral particle production has been detrimentally
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affected. Moreover, these data validate that the packaging signal remains
functional in the presence of the nsP1 point mutations described in this study.

Discussion
The capping of SINV genomic vRNAs can be modulated by point mutations
in nsP1
The data shown in Fig. 2.1 indicates that, in SINV, 5’ capping of the
genomic vRNA can be modulated via single point mutations in the nsP1 protein.
This is true for both increasing vRNA capping, as seen with SINV D355A, and
decreasing capping, as seen with SINV Y286A and SINV N376A. Moreover,
vRNA capping can also be modulated to different extents, as seen with SINV
Y286A and SINV N376A, which decreased vRNA capping by 25% and 75%,
respectively. The ability to change nsP1 capping efficiency in a controllable
manner opened up new avenues to explore the molecular and biological
importance of both the capped genomic vRNAs and the ncgRNAs during
infection in tissue culture models of infection and in vivo.
From the data above, we may conclude that a primary consequence of
mutating the SINV nsP1 protein is the alteration of vRNA capping. Nonetheless,
the alphaviral nonstructural proteins interact with one another during infection
[154-157]. Previous studies have shown that disrupting these interactions by
mutation results in poorer viral infection and, more specifically, leads to severe
defects in vRNA synthesis [154-156]. However, the disruption of nonstructural
protein interactions is unlikely with the nsP1 mutants reported in this study, as
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the phenotypes described for situations where the interactions between the
nonstructural proteins have been disrupted are inconsistent with what is reported
here. For example, several residues in nsP4 have been reported as important for
interactions with nsP1, such as G38L in nsP4 [154]. When this residue in nsP4
was mutated, viral infection exhibited decreased growth kinetics and a small
plaque phenotype. However, a hallmark of disrupting the nonstructural protein
interactions was the severely decreased synthesis of minus strand vRNA
throughout the course of infection [154, 156]. As seen in Fig. 2.5, none of the
nsP1 mutants examined in this study exhibited a significant deficit in production
of any viral RNA species, with the exception of a minor decrease in minus strand
vRNA synthesis by N376A. It is of note that the nsP4 G38L mutant was able to
be rescued by an additional mutation in nsP1 at N374 [154]. The nsP1 N374
mutation resulted in complete restoration of viral titer and partial restoration of
minus strand vRNA synthesis in the nsP4 G83L background compared to wild
type. While the effect of mutating nsP1 N374 on capping efficiency is not known,
one could speculate that, given its proximity to other residues which we have
shown alter capping activity, that modulating the capping efficiency of nsP1 could
be a way of coping with the detrimental nsP4 G38L mutation, which creates a
severe defect in RNA synthesis. In addition to this, a previous study has
reported that the region in nsP1 encompassing the SINV point mutations utilized
here possess little to no interaction with the nsP2 protein [157]. Thus, for the
reasons described above, the nsP1 residues mutated during this study are likely
not involved in mediating nonstructural protein interactions, and the resulting
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deficits in the viral lifecycle are not due to disrupted nonstructural protein
interactions.

SINV infection is more sensitive to increased capping than decreased
capping
Multiple studies have shown that polymorphisms in nsP1 have profound
effects on virulence. Mutations in regions of nsP1 have been shown to alter
vRNA synthesis, viral titer, viral sensitivity to IFN, and disease severity in vivo
[97, 154, 158]. Certain residues, such as nsP1 H39 in SINV, completely abrogate
viral infection by eliminating the methyltransferase activity of the nsP1 protein
[35, 134, 159]. Therefore, we expected that incorporating the point mutations
which alter viral capping would have impacts on viral infection. However, we
were surprised to find that while the increasing capping mutant was found to
have decreased viral growth kinetics, the decreased capping mutants were not
significantly different from wild type SINV (Fig. 2.2A). This result was especially
surprising when it was found that all three capping mutants had small plaque
phenotypes and decreased cell death, yet D355A was the only mutant to show
altered growth kinetics (Fig. 2.2B, C, and D). Serial passaging of the mutants
used in this study have indicated that they are stable for at least 4 sub-passages,
as no reversion events (based on plaque phenotype) were observed for any of
the SINV nsP1 mutants. This suggests that SINV is more detrimentally impacted
by changes which increase the amount of capped vRNA present than those
which decrease capping efficiency. Thus, increasing the capping efficiency of the
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SINV nsP1 protein, which effectively reduced the production of the ncgRNAs,
indicates that the ncgRNAs are biologically important to viral infection.

Altering capping leads to changes in genomic translation but not RNA
synthesis or subgenomic translation
As would be expected, changes in nsP1 capping efficiency correlated with
changes in genomic vRNA translation. In addition, the reduced presence of the
ncgRNAs correlated with increased translation of the viral genomic RNA
throughout infection, as can be seen with the increased capping mutant SINV
D355A. Furthermore, decreasing the capping efficiency of the nsP1 protein, as
evidenced by the SINV N376A mutant, modestly decreased translation.
Admittedly, the second decreased capping mutant, SINV Y286A, did not follow
the same pattern as the SINV N376A mutant. This may be due to the
comparatively minor decrease in capping efficiency caused by SINV Y286A not
being significant enough to consistently alter the vRNA population leading to
dysregulated genomic translation.
However, the increased translation exhibited by the SINV D355A mutant
did not lead to lasting compounding biological effects, at least in tissue culture
models of infection. For instance, despite there being more replication machinery
being produced early during SINV D355A infection, there were no overt
differences in the synthesis of any of the viral RNA species during the time points
tested (Fig. 2.5). This suggests that increasing or decreasing the production of
the nonstructural proteins alone is not enough to alter RNA synthesis over the
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long term in highly permissive tissue culture models of infection. Nonetheless,
due to technical limitations we were unable to accurately assess vRNA synthesis
earlier than two hours post infection. Hence, the possibility that vRNA synthesis
is enhanced very early during infection remains unaddressed.
Another unexpected result was that changes in capping efficiency seems
to affect subgenomic translation differently than genomic translation. The data
presented in Fig. 2.6 show that both the increased and decreased capping
mutants SINV D355A and SINV N376A demonstrate slight, biologically
unmeaningful, decreases in capsid production at 16hpi, despite having notable
differences in nonstructural gene expression (Figs. 2.3 and 2.4). This suggests
that either capping efficiency is regulated differently for the subgenomic RNA
than for the genomic RNA, resulting in no differences in capping efficiency for the
subgenomic RNA, or that translation of the subgenomic RNA is less dependent
on the presence of a 5’ cap than the genomic RNA during infection. The latter is
supported by previous studies which demonstrate that the eIF4F complex, which
includes the cap-binding eIF4E, is not needed in order to initiate translation of the
alphaviral subgenomic RNA [152, 160]. These previous studies, along with the
data presented here, suggests that translation of the subgenomic RNA is
unaffected, at least in part, by modulation of vRNA capping.
In addition to there being little effect on subgenomic translation, there was
also shown to be no differences in terms of host translational shutoff between
any of the capping mutants and WT SINV (Fig. 2.6C). This further supports that
the point mutations made in nsP1 are not negatively affecting interactions
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between nonstructural proteins, because disruptions between nsP1 and nsP4
have been previously found to negatively affect host translational shutoff [154].
Host translational shutoff, for SINV at least, has been largely attributed to the
translation of the structural proteins [161]. Therefore, it is unsurprising that there
is no change in host shutoff between the capping mutants and the WT SINV
given that there is little difference in subgenomic expression.

Decreased titer due to changes in capping caused by interference with
particle production
The decreased viral growth kinetics observed during SINV D355A
infection correlated remarkably with decreased particle production. However, the
congruence of the decrease in infectious units and viral particles infers that viral
infectivity is, more or less, identical for all of the viral strains. The discrepancy
between the two magnitudes of effect (an approximate 5-fold difference) are
likely due to confounding variations in the accuracy and precision of the two
measurements. Nonetheless, it remains possible that the viral particles have
differences in their basal infectivity. Studies examining earlier effects of the
ncgRNAs are ongoing and will be presented in a follow up study.
The observation that decreased particle production is the primary
molecular defect during SINV D355A infections suggests that increasing the
amount of capped genomic RNAs, thereby decreasing the number of ncgRNAs,
negatively impacts the assembly of nascent viral particles. Whether or not the
increased capping activity is directly, or indirectly, responsible for the packaging
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phenotype isn’t definitively known. Characterizations of SINV packaging indicates
selectivity remains intact during the SINV D355A assembly process despite
decreased particle production overall, as the packaging of subgenomic vRNAs
was not observed. This is indicative of a functional alphaviral packaging signal
despite the incorporation of minor point mutants into the region defined as the
packaging signal for SINV. Moreover, the SINV Y286A mutant which also resides
within the SINV packaging element lacks an appreciable packaging phenotype.
Thus, the assembly phenomena associated with the SINV D355A mutant cannot
be simply explained by disruption of the alphaviral packaging signal.
While the underlying mechanism is unclear, the data presented above
indicates that nonstructural protein expression is increased relative to wild type
parental virus, and remains increased well into the late stages of infection during
SINV D355A infections. Collectively, these data indicate that decreasing the
production of the ncgRNAs perturbs viral genomic RNA function beyond the
individual RNA level, as apparent compounding effects on the genomic RNA
population are observed. Precisely how the translationally inactive ncgRNAs
serve to modulate genomic vRNA function as a whole, leading to efficient particle
assembly, is unknown.
We propose that, as diagrammed in Fig. 2.8, during wild type infections,
the translationally inactive, ncgRNAs temper the molecular activities of the
translationally active, capped genomic vRNA population allowing for the temporal
progression of infection to lead to the assembly and release of viral particles. We
postulate that the ncgRNAs, due to their lack of translational capacity, interact
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with a unique set of host factors relative to the capped translationally competent
genomic RNAs. Collectively, these interactions lead to the development of a proassembly microenvironment by excluding host factors that either inhibit the
assembly process, or promote nucleocapsid disassembly. For instance, if the
ncgRNAs foster an non-translational environment through the interaction of host
factors, such as those found within stress granules, the 60S ribosomal subunit,
which is implicated in nucleocapsid disassembly would be excluded from the
local microenvironment, allowing assembly to occur unimpeded [26, 162].
However, when the genomic RNA population is altered by increasing the
efficiency of genomic RNA capping, such as observed with the SINV D355A
mutant, the increased and continuous translational activity of the genomic vRNA
culminates in the formation of a pro-translational vRNA “pool” that is refractory to
encapsidation and particle assembly. Work examining such possibilities are
ongoing in the Sokoloski lab and will be reported in the future.

Conclusions
Collectively these data affirm the existence and biological importance of
the ncgRNAs during SINV infection. This assertion is directly supported by the
capacity to modulate the capping activities of nsP1 protein via site directed
mutagenesis resulting in the increased production of XRN-1 resistant genomic
vRNAs without increased overall genomic RNA numbers. Moreover, the
preponderance of gene expression data indicating increased translation brought
about by increasing the capping of the genomic vRNA supports the existence of
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the alphaviral ncgRNAs at a functional level. Finally, the molecular
characterizations of SINV nsP1 mutant infections provides insight into the
biological importance of the ncgRNAs in regards to the regulation of alphaviral
infection at the molecular level.
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Figure 2.1. Point mutations in the nsP1 protein of SINV alter 5’ vRNA
capping efficiency. (A) Amino acid sequence alignment of selected alphavirus
nsP1 proteins. The individual nsP1 protein sequences of Sindbis (ViPR-U38305),
Venezuelan Equine Encephalitis (VEEV, ViPR-L01443), Chikungunya virus
(CHIKV, ViPR-DQ443544), and Ross River virus (RRV, ViPR-GQ433359) were
aligned by Clustal Omega. (B) An ITASSER predicted structure of the SINV nsP1
protein. Amino acid residues of importance are highlighted as followsRed=Y286, Green=D355, Blue=N376, Cyan=amphipathic helix, and the residues
involved in the methyltransferase activities, including H39 which binds to the
m7GMP

residue are pink. (C) A graph depicting the relative quantity of XRN-1

resistant vRNA isolated from viral particles produced by BKH-21 cells infected
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with wild-type SINV or the individual capping mutants 24hpi. (D) Identical to
panel C, with the exception that the viral genomic RNAs were enzymatically
decapped concurrent with XRN-1 treatment. All quantitative data shown
represents the means of a minimum of three independent biological replicates
utilizing 3 independent particle preparations, with the error bars indicating the
standard deviation of the means. P-Values, as indicated on the figure, were
determined by Student’s T-test.
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Figure 2.2. Altering viral capping efficiency negatively impacts viral
infection. (A) One-step growth kinetics of the individual capping mutants and
parental wild type SINV as observed in BHK-21 cells infected at an MOI of 0.5
PFU/cell. Statistical significance was determined by area under the curve
analysis. (B) Plaque morphology of wild type SINV and capping mutant viruses in
BHK-21 cells overlaid with 1 0.5% solution of Avicel at 24h post-infection. (C) A
graph indicating the average plaque diameter of the mutant viruses relative to
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wild type SINV. Size was determined by ImageJ software (NIH). (D) Cell viability
of BHK-21 cells infected with the individual capping mutants at 24hpi relative to
mock infected BHK-21 cells. All quantitative data shown represent the means of
at least three independent biological replicates, with the error bars representing
standard deviations of the mean. Statistical significance, as indicated within each
panel, was determined by Student’s t test.
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Figure 2.3. Translation of the genomic vRNA correlates with viral capping
efficiency. (A) Schematic diagram of the SINV nanoluciferase reporter used in
this study. (B) BHK-21 cells were infected with either parental wild type, or an
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individual SINV capping mutant nanoluciferase reporter strain. The level of
nanoluciferase activity was quantified at the indicated times post infection. C)
The nanoluciferase activity, as reported in panel B, normalized to wild type
expression at each individual time point to enable readers to identify differences
in translation. All the quantitative data shown represent the means of three
independent biological replicates, with the error bars representing standard
deviations of the mean. Statistical significances, as indicated in the figure, were
first determined using ANOVA analyses followed by post-hoc statistical analyses
by Student’s t test.
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Figure 2.4. nsP2 protein levels are impacted by mutation of the nsP1
protein. (A) BKH-21 cells were infected with wild type SINV or an individual
capping mutant at an MOI of 5 PFU/cell and assessed by western blotting to
determine the abundance of nsP2 at 8hpi. Actin is shown as a loading control. B)
Densitometric quantification of the nsP2 protein normalized to Actin levels at
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8hpi. Panels C and D) Western blots and densitometry analyses identical to
those described for panels A and B, with the exception that the timing of the
assay coincided to 12hpi. Panels E and F) Western blots and densitometry
analyses identical to those described for panels A and B, with the exception that
the timing of the assay coincided to 16hpi. The Western blot images shown are
representative of at least three independent biological replicates. All the
quantitative data shown represent the means of three independent biological
replicates, with the error bars representing standard deviations of the mean.
Statistical significances, as indicated in the figure, were first determined using
ANOVA analyses followed by post-hoc statistical analyses by Student’s t test.
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Figure 2.5. Altering vRNA capping efficiency impacts early RNA synthesis.
(A) BHK-21 cells were infected with either wild type parental SINV or an
individual capping mutant virus at an MOI of 5 PFU/cell. At 2 hours post infection,
the total cellular RNA was extracted and assessed for the absolute quantities of
the genomic, subgenomic, and minus-strand vRNAs by qRT-PCR. (B and C)
Identical to panel A with the exceptions that the time points are 4 and 8 hours
post infection, respectively. All the quantitative data shown represent the means
of three independent biological replicates with the error bars representing
standard deviations of the mean. Statistical significances, as indicated in the
figure, were first determined using ANOVA analyses followed by post-hoc
statistical analyses by Student’s t test. P-Values as determined by Student’s t
test are represented by *, p<0.05. **, p<0.01. ***, p<0.001. #, one of the
biological replicates was below limit of detection precluding meaningful statistical
analysis.
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Figure 2.6. Subgenomic gene expression is unaffected by altering SINV
vRNA capping. (A) BHK-21 cells were either mock treated or infected with wild
type SINV or an individual capping mutant at an MOI of 10 PFU/cell. At 14hpi,
the cells were pulsed with L-AHA for a period of 2 hours. Afterwards, the cells
were harvested and equal cell volumes of cell lysate were analyzed by SDSPAGE and fluorescent imaging. The data shown are representative of three
independent biological replicates. (B) Densitometric quantification of the SINV
capsid protein, with intensity relative to wild-type SINV shown. (C) Densitometric
quantification of the host actin protein with intensity relative to wild type SINV. All
the quantitative data shown represents the means of three independent
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biological replicates with the error bars representing standard deviations of the
mean. Statistical significance was determined by Student’s t test.
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Figure 2.7. Analysis of SINV particle production. A) BHK-21 cells were
infected with either wild-type SINV or an individual capping mutant at an MOI of 5
PFU/cell. At 24hpi the total number of viral particles produced was measured
using qRT-PCR. Data shown represents the means of at least 6 independent
biological samples. B) Quantitative determination of the composition of the
encapsidated viral RNAs in mature extracellular viral particles. Samples of virus
containing supernatants were assessed to determine the absolute quantities of
the genomic and subgenomic RNAs via standard curve qRT-PCR. All the
quantitative data shown represent the means of three independent biological
replicates, with the error bars representing standard deviations of the mean.
Statistical significances, as indicated in the figure, were first determined using
ANOVA analyses followed by post-hoc statistical analyses by Student’s t test.
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Figure 2.8. Proposed model of how increasing genomic vRNA capping
negatively impacts viral infection. Wild-type SINV infection produces a low
capped population of vRNAs that are weakly pro-translational and enables
efficient particle production (top). Conversely, the increased capping nsP1
mutant D355A produces a population of vRNAs that are largely capped and
therefore strongly pro-translational, which subsequently leads to impaired particle
production compared to wild-type infection.
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CHAPTER 3
PRODUCTION OF NONCAPPED GENOMIC RNAS IS CRITICAL TO SINDBIS
VIRUS DISEASE AND PATHOGENICITY2

Summary
Alphaviruses are positive-sense RNA viruses that utilize a 5’ cap structure
to facilitate translation of viral proteins and to protect the viral RNA genome.
Nonetheless, significant quantities of viral genomic RNAs that lack a canonical 5’
cap structure are produced during alphaviral replication and packaged into viral
particles. However, the role/impact of the noncapped genomic RNA (ncgRNA)
during alphaviral infection in vivo has yet to be characterized. To determine the
importance of the ncgRNA in vivo, the previously described D355A and N376A
nsP1 mutations, which increase or decrease nsP1 capping activity respectively,
were incorporated into the neurovirulent AR86 strain of Sindbis virus to enable
characterization of the impact of altered capping efficiency in a murine model of
infection. Mice infected with the N376A nsP1 mutant exhibited slightly decreased
rates of mortality and delayed weight loss and neurological symptoms, although
levels of inflammation in the brain were similar to wild type infection. Although the

2

This chapter is adapted from work published in mBio, 2020, Volume 11, Issue 6 with the same
title under a Creative Commons Attribution (CC BY) license 163. LaPointe, A.T., et al., Production
of Noncapped Genomic RNAs Is Critical to Sindbis Virus Disease and Pathogenicity. mBio, 2020.
11(6).
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D355A mutation resulted in decreased antiviral gene expression and increased
resistance to IFN in vitro, mice infected with the D355A mutant showed significantly
reduced mortality and morbidity compared to mice infected with wild type virus.
Interestingly, expression of proinflammatory cytokines was found to be significantly
decreased in mice infected with the D355A mutant, suggesting that capping
efficiency and the production of ncgRNA are vital to eliciting pathogenic levels of
inflammation. Collectively, these data indicate that the ncgRNA have important
roles during alphaviral infection and suggest a novel mechanism by which
noncapped viral RNA aid in viral pathogenesis.

Introduction
Alphaviruses are positive-sense, single-stranded RNA arboviruses that
are capable of causing severe disease. The natural enzootic transmission cycle
of these viruses is between a mosquito vector and a mammalian host, typically
rodents or birds, although epizootic spillover events can occur that result in
infection of humans and equids. Alphaviruses are broadly categorized as either
arthritogenic or encephalitic based on disease symptomology. The arthritogenic
alphaviruses, such as Chikungunya virus (CHIKV) and Ross River Virus (RRV)
are capable of causing disease ranging from mild febrile illness to severe
polyarthralgia, which can persist anywhere from weeks to years following
infection [4, 11, 164]. In contrast, the encephalitic alphaviruses, such as
Venezuelan Equine Encephalitis virus (VEEV) and some strains of Sindbis virus
(SINV), like the AR86 strain used in this study, can cause mild to severe
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neurological symptoms, including encephalitis that can potentially lead to the
death of the host [11, 12, 165]. While alphaviruses pose a large threat to public
health, there are currently no safe and effective vaccines or antiviral therapies to
prevent or treat alphaviral disease.
Alphaviruses produce three RNA species during infection: the genomic
strand, which encodes the nonstructural proteins; the minus-strand RNA
template; and the subgenomic RNA, which encodes the structural proteins. Both
the genomic and subgenomic RNAs have a type 0 cap structure added to their 5’
ends to facilitate translation and protect the 5’ end of the transcripts [129-131].
The addition of the cap structure to the 5’ end of viral RNAs is primarily carried
out by nonstructural proteins 1 and 2 (nsP1, nsP2). NsP2 removes the 5’ γphosphate from the nascent vRNA molecule while, in a separate reaction, the
methyltransferase domain of nsP1 catalyzes the addition of a methyl group from
S-adenosylmethionine to a GTP molecule, forming a covalent m7GMP-nsP1
intermediate [40, 132]. The m7GMP moiety is then transferred to the 5’end of the
vRNA molecule by the guanylyltransferase activities of nsP1, resulting in the
7meGppA type 0 cap structure [133].
In response to the lack of preventatives or treatments, targeting the
alphaviral replication machinery has been a popular approach for developing
potential antiviral therapies. Capping of the genomic and subgenomic vRNA is
vital for successful viral replication, as mutations which completely inhibit capping
of the viral RNA render the virus noninfectious. Thus, because nsP1 is
responsible for the alphaviral capping process, it has been a popular target for
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antiviral research. In particular, a number of compounds have been developed
which inhibit nsP1 capping activity and reduce viral replication in vitro, but, to
date, none have been tested for efficacy against alphaviral infection in vivo [166169]. In addition to the development of drugs against nsP1 activity, multiple
residues in nsP1 have also been identified as determinants for alphaviral
virulence, however the impact of these residues on alphaviral capping efficiency
has never been delineated. The SINV nsP1/nsP2 cleavage mutant T538I has
been shown to determine pathogenicity in mouse models of infection by altering
nonstructural polyprotein processing and the virus’ sensitivity to interferon [101,
170]. More recently, a group of six mutations in the nsP1 of RRV have also been
shown to attenuate alphaviral disease in mice, although the mechanism of
attenuation and the impacts of these mutations on alphaviral replication have yet
to be fully characterized [97, 98]. These studies illustrate the significance of nsP1
to alphaviral infection and pathogenicity, but have yet to determine the
importance of alphaviral capping efficiency and the production of the ncgRNAs to
in vivo infection.
While capping of the viral RNA is critical to viral protein expression and
viral replication, we have previously shown that the genomic vRNA are not
universally capped, and that a significant proportion of the alphaviral genomic
RNA produced and packaged during infection lack the 5’ cap structure [99]. In
addition, our recently published study showed that the proportion of noncapped
genomic RNA (ncgRNA) produced during SINV infection could be altered using
point mutations in nsP1 to modulate capping activity [171]. Specifically,
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incorporating a D355A mutation in the nsP1 of SINV resulted in increased
capping efficiency, and therefore decreased ncgRNA production, relative to wild
type SINV. Alternatively, a N376A mutation in nsP1 resulted in decreased
capping efficiency and increased ncgRNA production. By utilizing these
mutations to alter ncgRNA production, we were able to show that increasing the
capping efficiency of nsP1 was detrimental to SINV infection in tissue culture
models of infection, while decreasing nsP1 capping efficiency did not significantly
affect viral titer or overall replication.
However, the presence or lack of a phenotype in vitro is not always
indicative of what will occur during infection in vivo. As such, the goal of this
study was to determine the effect of altered ncgRNA production on alphaviral
pathogenesis by using the previously described nsP1 capping mutants in a
mouse model of infection. The data presented here show that modulating
ncgRNA production through the use of the D355A and N376A point mutations to
alter nsP1 capping efficiency in nsP1, has a profound impact on alphaviral
pathogenesis. In specific, decreasing capping efficiency resulted in increased
sensitivity to type-I IFN and a slight decrease in mortality. Surprisingly, increasing
capping efficiency resulted in almost complete abrogation of morbidity and
mortality, despite showing increased resistance to type-I IFN, due to reduced
immune infiltration and production of inflammatory cytokines in the brain.
Collectively, our findings indicate that the ncgRNA are important in determining
the host immune response to viral infection and play a critical novel role in
alphaviral pathogenesis.
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Materials and Methods
Tissue culture cells. Baby Hamster Kidney 21 (BHK-21) fibroblast cells (a gift
from Dr. R. W. Hardy, Indiana University – Bloomington) and interferon
competent L929 mouse fibroblast cells (a gift from Dr. P. Danthi, Indiana
University - Bloomington) were maintained in minimal essential media (MEM;
Cellgro) containing fetal bovine serum (FBS; Atlanta Biologicals), 1% PenicillinStreptomycin (Cellgro), 1% nonessential amino acids (Cellgro), and 1% Lglutamine (Cellgro). SK-N-BE(2) human nerve cells (a gift from Dr. L. Beverly,
University of Louisville) were maintained in Dulbecco's Modified Eagle Medium
(DMEM)/F12 media containing 10% FBS, 1% Penicillin-Streptomycin, and 1% Lglutamine. All cell lines were cultured at 37o C and 5% CO2 in a humidified
incubator. Regular passaging using standard subculturing techniques was used
to maintain low passage stocks.

Generation of AR86 SINV capping mutants. The AR86 SINV nsP1 mutants
used in this study were generated by Gibson Assembly via the use of a Gibson
Assembly HiFi 1-step kit (SGI), using a restriction-digested AR86 cDNA plasmid
and a synthetic DNA fragment, according to manufacturer’s instructions [165].
Mutants were verified by whole-genome sequencing; full-genome sequences are
available upon request.
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Production of wild-type and mutant SINV Stocks. Wild-type, D355A, and
N376A SINV AR86 were prepared by electroporation, as previously described
[137]. Approximately 2.8x106 BHK-21 cells were electroporated with 10μg of in
vitro-transcribed RNA. This was done using a single pulse at 1.5kV, 12mA, and
200 Ω from a Gene Pulse Xcell system (BioRad) as previously described [171].
Afterwards, cells were incubated under normal conditions until cytopathic effect
was apparent, at which point the supernatant was collected, clarified via
centrifugation at 10,000xg for 10min at 4oC, and aliquoted into small volume
stocks which were stored at -80oC for later use.

Capping Assay. To define the impact of the nsP1 mutations on the capping
activity of the alphaviral replicase complex, a linker-ligation mediated approach
was used. Briefly, BHK-21 cells were infected with the aforementioned SINV
AR86 nsP1 mutants at an Multiplicity of Infection (MOI) of 5 Infectious Units (IU)
per cell, and at 16 hours post infection (hpi) total RNA was extracted from the
cells via TRIzol. As our previous studies have indicated that the 5’ end of the
noncapped viral transcripts are poly-phosphorylated, the total RNA samples must
be initially dephosphorylated prior to completing the linker-ligation method (which
requires a 5’ monophosphate) [99]. To this end, 1ug of RNA was
dephosphorylated via treatment with Antarctic Phosphatase (NEB, M0289S) as
per the manufacturer’s instructions. After a 30 minute incubation period at 37⁰C,
the Antarctic Phosphatase was heat inactivated by incubating the reaction
mixture for 2 minutes at 80⁰C prior to rapid cooling on ice. The dephosphorylated
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RNAs were then equally divided into two reactions to further prepare the
noncapped and capped transcripts for linker-ligation and qRT-PCR analysis. To
enable the detection of the noncapped viral RNAs, the dephosphorylated RNAs
were treated with T4 Polynucleotide Kinase (PNK; NEB, M0201L) as per the
manufacturer’s instructions. In parallel, the capped RNAs were further prepared
for linker-ligation via incubation in the presence of RNA 5’ Pyrophosphohydrolase
(RppH; NEB, M0356S), as per the manufacturer’s instructions. Both the T4 PNK
and RppH reactions were incubated for a period of 30 minutes at 37ºC prior to
phenol chloroform extraction and ethanol precipitation. The RNA pellets were
resuspended in 20ul of nuclease-free water and used as the input materials for
the linker-ligation reaction described below to enable the detection of the
noncapped and capped vRNAs via qRT-PCR.
The prepared RNAs were then ligated to an RNA linker that was blocked
on the 5’ end with a 9 carbon spacer (RNA Linker- 5’-5Sp9GUUCAGAGUUCUACAGUCCGACCCAUC-3’) via T4 RNA Ligase 1. Briefly,
each 30ul reaction mixture consisted of 0.5ugs of prepared RNA (as described
above), 1X T4 RNA Ligase Buffer, 1mM ATP (final concentration), 1.66uM RNA
Linker Oligo (final concentration), 10 Units (U) of T4 RNA Ligase 1 (NEB,
M0204S), and 40U of RNAse Inhibitor (NEB, M0314S). The linker-ligation
reactions were incubated at 25⁰C for a period of 2 hours prior to phenol
chloroform extraction and ethanol precipitation. The linker-ligated RNAs were
resuspended in 20ul of nuclease-free water, and 5ul of the ligated RNAs were
used as the input for Reverse Transcription (RT) reactions using OneScript Plus
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RT (Abmgood, G237) as per the manufacturer’s instructions. To enable the
specific amplification of the viral genomic RNA, the RT reactions were primed
with SINV.nSP1.R oligo (5’-AACATGAACTGGGTGGTGTCGAAG-3’). The
composition of the SINV genomic RNA 5’ ends were then quantitatively assessed
via qRT-PCR as previously described using primer sets specific for the RNA
linker as well as for nsP1 [99]. The amount of linker-containing genomic RNAs
relative to the total genomic RNA level was then calculated using the ΔΔCT
method in order to determine the ratio of capped or noncapped RNA present,
depending on the sample treatment described above. The primers used for this
experiment are listed in Supplemental Table 1.

Analysis of viral growth kinetics. To determine if the mutation of the SINV
nsP1 protein negatively impacted AR86 SINV infection, one-step viral growth
kinetics for each capping mutant were assayed in tissue culture models of
infection. BHK-21 cells were seeded in a 12-well plate and incubated under
normal conditions until cell monolayers were 80-90% confluent. The cells were
then infected with either wild-type virus or the individual capping mutant virus at
an MOI of 5 IU/cell and the virus was allowed to adsorb for 1 h. The inoculum
was then removed, the cells were washed with 1x phosphate buffered saline
(PBS) to remove any unbound viral particles, and whole medium supplemented
with 25mM HEPES was added. The cells were incubated at 37 o C and tissue
culture supernatants were harvested (and the media replaced) at the indicated
times post infection. Viral titer was then determined via plaque assay.
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Quantification of infectious virus by plaque assay. In order to determine
infectious viral titer of all viral samples produced during this study, standard
virological plaque assays were used. To summarize, BHK-21 cells were seeded
in 24-well plates under normal incubation conditions until the cell monolayers
were 80-90% confluent. At that point, the cells were inoculated with 10-fold serial
dilutions of virus containing samples followed by a 1-hour adsorption period.
Afterwards, cells were overlaid with a solution of 0.5% Avicel (FMC Corporation)
in 1x media for 48 h [138]. The monolayers were then fixed with formaldehyde
solution (3.8% formaldehyde-1x PBS) for at least 1 h. The overlay was then
removed, and the plaques were visualized via crystal violet staining.

Western Blot. To determine whether or not altering the capping efficiency
impacted the expression of the SINV nonstructural genes, the expression of
nsP2 was assessed via Western blotting. Briefly, whole-cell lysates were
generated from BHK-21 cells that were infected with either wild type SINV AR86,
one of the aforedescribed nsP1 mutants, or Mock infected. At 8 hours post
infection, the cells were lysed via the addition of RIPA buffer (50mM Tris-HCL
(pH 7.5) – 50mM NaCl – 1% (v/v) Nonidet P40 (NP-40) – 0.5% (w/v) SDS –
0.05% (w/v) sodium deoxycholate – 1mM EDTA) followed by vigorous vortexing
prior to storage at -80⁰C until further use. Equal amounts of whole-cell lysates
were resolved using SDS-PAGE and transferred to nitrocellulose membranes for
downstream immunodetection. The resulting blots were probed for anti-SINV
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nsP2 polyclonal sera (a gift from R.W. Hardy at Indiana University-Bloomington)
and anti-Actin (ThermoFisher, clone mAGGEa), and probed with the appropriate
HRP-labeled secondary antibodies using the iBind Flex Western System with
HRP detection / blotting reagents (ThermoFisher). Detection of the SINV nsP2
and host Actin proteins was accomplished via chemiluminescence with
SuperSignal West Pico PLUS Chemiluminescent Substrate (ThermoFisher,
34579) detected by an Azure C200 Imaging Station (Azure Biosystems, C200).

RNA Kinetics. BHK-21 cells were infected with either wild type SINV AR86, or
one of the aforementioned SINV nsP1 mutants at an MOI of 5 IU/cell. At the
indicated times post-infection, the total RNA was isolated from the infected cells
via TRIzol reagent, as according to the manufacturer’s instructions. Paired RT
reactions were assembled using 1ug of total cellular RNA and primer sets
designed to prime the synthesis of cDNA from the viral RNA species in a
transcript specific manner. Briefly, the positive-sense RNAs were primed for
cDNA synthesis using SINV.nsP1.R (5’-AACATGAACTGGGTGGTGTCGAAG-3’)
and SINV.E1.R (5’-ATTGACCTTCGCGGTCGGATACAT-3’), and the negative
sense RNAs were primed for cDNA synthesis using SINV.nsP1.F (5’AAGGATCTCCGGACCGTA-3’). All RT reactions also included an oligo priming
for the mammalian 18S rRNA, Mam.18S.R (5’-AGTCGGCATCGTTTATGGTC3’). qRT-PCR detection of the viral RNA species was accomplished using a
standard curve analysis and subtractive method as previously described [171].
To determine the amount of subgenomic vRNA present, the absolute quantities
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of RNA detected with the nsP1 primer set were subtracted from that detected
with the E1 primer set, as the E1 primer set will detect both the genomic and
subgenomic RNAs, but the nsP1 primer set will only detect the genomic RNA.
Primer pairs are listed in Supplemental Table 1.

Type-I IFN sensitivity assay. L929 cells were seeded in a 48 well plate and,
upon reaching 80-90% confluency, were inoculated with either wild-type parental
virus or one of the individual capping mutants at an MOI of 10 IU/cell. After a 1 h
adsorption period, the inoculum was removed, the cells were washed twice with
1x PBS, and whole media was added. At the indicated times post infection, 20
international units (IU) of murine type-I IFN (R&D Systems) was added to the
media. Supernatants were collected at 24hpi and viral titer was determined by
plaque assay. To calculate the relative sensitivity, the difference in viral titer
between the type-I IFN treated and untreated infections was calculated at each
time point for each virus. These differences were then calculated relative to the
differences seen during wild-type SINV infection in order to determine relative
sensitivity to type-I IFN.

Detection of ISG and IFNβ transcripts. To determine abundance of IFNβ and
the listed ISG transcripts, L929 cells were seeded in a 24-well plate and, upon
reaching 80-90% confluency, were inoculated with wild-type SINV or one of the
capping mutants at an MOI of 10 IU/cell. Additionally, L929 cells were mock
infected with PBS to determine baseline IFNβ and ISG expression. After a 1h
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adsorption period, the inoculum was removed, the cells were washed once with
1x PBS, and whole media was added. At the specified timepoints, media was
removed, the cells were washed once with 1x PBS, and cell lysates were
harvested and RNA was extracted using acidic guanidinium thiocyanate-phenolchloroform extraction [172]. The RNA was then DNAse treated and precipitated
via phenol-chloroform extraction. Following precipitation, 1μg of RNA was
reverse transcribed using random hexamer primer and qRT-PCR was carried out
as described above with primer sets obtained from PrimerBank. The sequences
of these primers may be found in the Supplemental Materials associated with this
manuscript. Data was first normalized to GAPDH to account for any differences
in total RNA level between samples. Data from the wild-type SINV, D355A, and
N376A infections were then also normalized to nsP1 to account for differences in
viral RNA levels that were present. Fold change in IFNβ and ISG expression was
then calculated relative to what was observed during mock infection.

Mouse Experiments. Four-week old C57BL/6 mice were obtained from Jackson
Laboratory and were inoculated in the left, rear footpad with 1000 PFU of virus in
diluent (1x PBS) in a volume of 10μL. Mock-infected animals were injected with
diluent alone. Mice were monitored for neurological signs of disease and
weighed twice daily. A total of 130 mice were used in this study. For mortality
studies, 2 biological replicates were completed with 4 animals were used per
group, with a total of 4 groups. For titer studies, 6 animals were used per group,
with a total of 3 groups, and a total of 5 timepoints. Eight additional mock infected
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mice were harvested and paired with the above timepoints. Neurological scoring
was as follows: 0 = No signs of overt disease, and normal behavioral activity; 1 =
Abnormal trunk curl, grip, or tail weakness (1 of 3); 2 = Abnormal trunk curl, grip,
or tail weakness (2 of 3); 3 = Absent trunk curl, lack of gripping, tail paralysis; 4 =
Pronounced dragging of one or more limbs; 5 = hind or fore limb paralysis. On
the termination day for each experiment or when mice met endpoint criteria
(neurological scores of 5 or 4 if the animal was unable to obtain food or water), or
weight loss greater than 20% of initial body weight, the mice were sedated with
isoflurane and euthanized by thoracotomy. Blood was then collected and serum
obtained by collecting blood in serum separator tubes. Following exsanguination,
tissues were collected by dissection. Tissues were then placed in 1x PBS and
homogenized using Kimble BioMasher II closed system micro tissue
homogenizers. Ankle tissue was processed by bead beating using a Bead Ruptor
4 (Omni International). The infectious virus present in the tissue was quantified
by plaque assay.
For histology, uninfected and SINV infected mice brains were removed at
day 7 post infection and were divided in half sagitally. One half was used to
assess viral titer (described above), while the remaining half was fixed in 4%
formaldehyde and sectioned in paraffin. Tissue sections were then stained with
haematoxylin and eosin (H&E). Pathological changes were scored by a board
certified veterinary pathologist (through the Comparative Pathology Core
Services facility, Iowa State University) in the indicated categories and regions of
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the brain were scored as follows: 0=normal, 1=minimal, 2=mild, 3=moderate,
4=severe.

Detection of viral genome and cytokine transcripts in mouse tissues. To
measure the level of viral genome and cytokine transcripts in tissues of infected
mice, RNA was extracted from tissue homogenate using acidic guanidinium
thiocyanate-phenol-chloroform extraction. The RNA was then DNAse treated and
precipitated via phenol-chloroform extraction. Following precipitation, 1μg of RNA
was reverse transcribed using Protoscript II reverse transcriptase (NEB) and
random hexamer primer. The RNA genome was detected using BrightGreen
Express qPCR master mix (Abmgood) and the following primer set specific for
nsP1= F: 5-AAGGATCTCCGGACCGTA-3, and R: 5AACATGAACTGGGTGGTGTCGAAG-3. A standard curve of known
concentrations was used to determine the absolute quantities of viral genomic
RNAs. Cytokine transcripts were detected using TaqMan Fast Advanced Master
Mix and the Applied Biosystems TaqMan Array Mouse Immune Response plates
(Catalog number:4414079) according to manufacturer’s instructions.

Neuron Viability. Neuron viability was determined using a previously described
method of ethidium bromide and acridine orange staining [173-175]. SK-N-BE(2)
cells were seeded in a 96-well plate and, upon reaching 80-90% confluency,
were inoculated with either wild-type SINV or one of the capping mutants at an
MOI of 30 IU/cell. After a 1 h adsorption period, the inoculum was removed, the
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cells were washed once with 1x PBS, and DMEM/F12 media was added. At
24hpi, cell viability was assessed using ethidium bromide/ acridine orange
staining described in Ribble et al. Briefly, the 96-well plate was centrifuged at
1,000 RPM for 5 min using an Allegra 25R model centrifuge (Beckman Coulter)
with inserts for 96-well plates. Following centrifugation, 8μL of EB/AO dye
solution (100μg/mL ethidium bromide and 100μg/mL acridine orange in 1x PBS)
was added to each well. Cells were viewed using an epifluorescence
microscope. Tests were done in triplicate and a minimum of 100 total cells per
well were counted using ImageJ.

Animal Ethics and Research. This study was carried out in strict accordance
with the recommendations described in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health. The protocol was
approved by the Institutional Animal Care and Use Committee of the University of
Louisville (Approval #17-140). All manipulations which could result in acute pain
or distress were performed under isoflurane anesthesia.

Statistical Analysis. Unless otherwise stated, the quantitative data presented in
this study represent the means of data from a minimum of three independent
biological replicates. The in vivo studies described in this study were performed
in duplicate using two independent preps of viral stocks. An area-under-the-curve
approach was used to statistically assess the growth curve data presented in
Figure 3.1D to determine the differences in viral growth kinetics through the
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course of the assay. Comparative samples were statistically analyzed as
previously described [137], using variable bootstrapping where appropriate. The
survival data presented in Figure 3.6 were statistically analyzed using the log
rank test. Student’s t test was used to determine the P values associated with
individual quantitative data sets. Significance for data presented in Figure 3.10
was determined using the Benjamini and Hochberg correction, and the corrected
p-Values are shown in Fig. 3.10 panel B.

Results
Altering Capping Efficiency Is Detrimental To Viral Growth Kinetics In
Neurovirulent SINV In Vitro.
Given our previously reported findings describing the molecular phenotypes
of the nsP1 mutants in tissue culture models of infection, we were interested in
characterizing how altering ncgRNA production impacted SINV infection in vivo.
However, our previous characterizations of the capping mutants were done using
a Toto1101-derived strain of SINV, which is tissue culture adapted and does not
cause disease in adult wild type mice. Rather than rely on very young mice or
mouse models with deficiencies in IFN competency to assess pathogenesis, we
elected to change the SINV strain used to allow assessments in adult wild type
mice. Thus, we incorporated the D355A and N376A nsP1 mutations into the AR86
background of SINV, a neurovirulent strain capable of causing lethal disease in an
adult mouse model.
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To confirm that these point mutations had similar phenotypes in the AR86
background as compared to the previously used Toto1101-derived background,
the proportion of capped and noncapped genomic RNAs were quantified in BHK21 cells at 16hpi (Figure 3.1A-C). For wild type AR86 SINV, approximately half of
the genomic RNA was found to be capped. This is consistent with what was
previously found for the Toto1101-derived SINV, which also exhibited a
capped:noncapped ratio of 1:1 at the equivalent time during infection [99].
Specifically, the D355A nsP1 mutation resulted in production of an RNA population
consisting of 4-fold more capped RNA than noncapped RNA, whereas the N376A
nsP1 mutation produced a population with 4-fold more noncapped RNA than
capped RNA (Figure 3.1A). When compared to wild type AR86, the D355A mutant
produced significantly more capped vRNA and significantly less ncgRNA (Figure
3.1B and C). Conversely, the N376A mutant produced significantly less capped
vRNA and significantly more ncgRNA compared to wild type SINV. Although the
absolute magnitude by which capping efficiency was affected by the nsP1
mutations appears to be different in the AR86 strain compared to that observed for
the previously used Toto1101-derived strain, the trend of the D355A mutation
increasing capping efficiency and the N376A mutation decreasing capping
efficiency remained the same [171].
In addition to confirming the impact of the nsP1 mutations on vRNA capping
in the AR86 background, viral growth kinetics were also assessed in BHK-21 cells
(Figure 3.1D). Similar to what we have reported previously, increasing the capping
efficiency of nsP1 with the D355A mutation resulted in an approximately 1.5 log
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decrease in viral titer over the course of infection. Likewise, decreasing capping
efficiency with the N376A mutation also resulted in a significant decrease in viral
growth kinetics. While the phenotype associated with the N376A mutant was more
dramatic in the AR86 strain than what was reported in our previous study, this
might be explained by the fact that the AR86 strain of SINV is not adapted for
replication in tissue culture like the previously used Toto1101 strain. Therefore, the
impact of the N376A mutation on replication is likely exacerbated in tissue culture
systems for the AR86 strain, leading to the significantly reduced viral growth
kinetics seen in Fig. 3.1D.
To further confirm that the nsP1 mutants did not introduce gross lifecycle
defects in the AR86 background, viral translation was measured. To assess how
the nsP1 capping mutations affected viral translation, BHK-21 cells were infected
with either wild type SINV or one of the nsP1 capping mutants, and the relative
expression of the SINV nsP2 protein was detected via Western blotting (Figure
3.2A). Densitometry analysis of the fully cleaved form of nsP2 revealed no
quantitative differences across the SINV AR86 nsP1 mutant strains (Figure 3.2B).
Despite no apparent differences in fully processed nsP2 levels, increased levels
of nonstructural polyprotein were detected in the SINV nsP1 D355A mutant via
comparative densitometry (Figure 3.2C). Furthermore, comparing the total signal
detected by the anti-nsP2 polyclonal serum reveals slightly enhanced
nonstructural gene expression in the D355A nsP1 mutant, consistent with our
previous observations using the Toto1101-derived nsP1 mutants. These data are
suggestive of increased or ongoing nonstructural protein synthesis in the D355A
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background. As supported by the equivalent levels of fully processed nsP2, the
processing of the nonstructural polyprotein likely occurs at a rate that is unaffected
by the level of translation of the polyprotein. Thus, increasing the capping efficiency
of the nsP1 protein led to increased nonstructural gene expression. Unlike what
was previously found, the N376A decreased capping mutant showed no difference
in viral translation compared to wild type SINV.
On the basis of our previous examinations of the Toto1101-derived SINV
nsP1 mutants, we postulate that differences in viral translation may be more
pronounced during the earliest stages of infection. Previously we have utilized
nanoluciferase reporter viruses to quantitatively assess viral gene expression in a
highly sensitive manner. Unfortunately, the inclusion of a nanoluciferase reporter
into the nsP3 protein of SINV AR86 has been found to be highly attenuating,
precluding the detailed quantitative assessment of early SINV AR86 translation.
In addition to viral translation, viral RNA synthesis / accumulation was also
assessed to determine if the nsP1 capping mutations affected RNA kinetics in the
AR86 strain of SINV. Similar to what was shown in the Toto1101-derived
background, there were no significant differences for any of the vRNA species
produced by either nsP1 mutant at any of the measured timepoints compared to
wild type SINV (Figure 3.3A-C) [171].
Taken together, we can conclude that the D355A and N376A nsP1
mutations affect capping efficiency and viral nonstructural protein expression in the
AR86 strain of SINV in a manner that is similar to the previously used Toto1101derived background. We can also conclude that the decreases seen in viral titer
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between the nsP1 capping mutants and wild type SINV are not due to deficits in
viral translation or RNA synthesis, but are rather due to changes in the proportion
of ncgRNA produced by each mutant. Overall, the recapitulation of the original
D355A and N376A capping phenotypes in the AR86 background provided a
means by which the biological impact of the ncgRNAs on viral infection and
pathogenesis could be assessed using an adult wild type mouse model. However,
since our data suggest that the early events of the viral lifecycle may be altered by
modulating capping efficiency, we decided to first characterize the engagement of
the AR86-derived nsP1 mutants with the host innate immune response at a cellular
level prior to utilizing a small animal model of SINV infection [171].

Modulating ncgRNA Production Alters The Host Type-I Interferon Response
To SINV Infection.
The capacity of the host cell to detect viral infection and mount an antiviral
response by upregulating interferon and interferon stimulated gene (ISG)
expression is an important aspect of viral infection. As such, we were interested in
determining whether changes in viral capping efficiency would impact the
stimulation of the host type-I IFN response. To assess the extent to which the nsP1
mutants elicited an interferon response, interferon competent L929 cells were
infected with either wild type SINV or one of the capping mutants and then the
expression of IFNβ was measured at the transcriptional level using qRT-PCR
(Figure 3.4A). For this experiment, in addition to quantitatively assessing IFNβ
transcripts throughout the viral lifecycle, we also quantified the transcript
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abundance of select ISGs with well-established times of maximal expression post
viral infection, so that we could more accurately determine the host antiviral
response over the course of infection [176]. As such, CXCL10 and IFIH1 were
used to determine the ISG expression at 6 and 8hpi, Viperin and MX2 at 16hpi,
and OAS2 and BST-2 at 24hpi (Figure 3.4B-E).
Infection with the D355A mutant resulted in significantly reduced IFNβ
expression compared to wild type SINV at 8 and 16hpi, while N376A infection
resulted in significantly greater IFNβ expression at 6 and 24hpi (Fig. 3.4A). In
regards to ISG transcript levels, infection with the N376A mutant resulted in
significantly increased ISG expression compared to wild type SINV at 6hpi, but
transcript abundance was roughly equivalent to wild type infection at 8hpi (Figure
3.4B-D). However, by 24hpi, ISG expression levels were once again significantly
increased (Figure 3.4E). In contrast, ISG expression levels in response to the
D355A mutant was significantly decreased compared to wild type SINV until 24hpi,
where OAS2 expression was still significantly decreased, but BST2 expression
was similar to wild type.
Overall, infection with the increased capping mutant, D355A, led to a mostly
decreased host antiviral response compared to what was seen during wild type
infection, while the decreased capping mutant, N376A, elicited a response that
was mostly increased compared to wild type SINV. Taken together, these results
illustrate that modulating ncgRNA production has a significant impact on the
induction of the host type-I IFN response.
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Sensitivity To Type I IFN Correlates With Capping Efficiency In Tissue
Culture.
Given that altering capping efficiency affected viral gene expression, and
altered the induction of the host type-I IFN response, we were interested to see if
changes in ncgRNA production affected the virus’s sensitivity to IFN treatment. In
other words, we have shown that altering capping efficiency impacts how much
IFN is produced, but does altering SINV capping efficiency affect the virus’s
capacity to resist IFN treatment when the cells are treated with equal amounts of
type-I IFN? To determine whether changes in ncgRNA production affected the
sensitivity of the nsP1 mutant viruses to exogenous type-I IFN, IFN-competent
L929 cells were infected with either wild type or a SINV nsP1 mutant virus and
recombinant type-I IFN was then added at 0, 1, 2, 3, or 4 hours post infection and
viral titer was measured at 24hpi (Figures 3.5A-C) [175].
During wild type SINV infection, viral titer was reduced by ~2 logs when IFN
was added at 0 hpi, with maximum titer increasing regularly as the time of IFN
addition was delayed. IFN treatment at 4 hpi did not impact SINV AR86 replication
as viral titers were equivalent to those of the no IFN control (Fig. 3.5A). The D355A
mutant, which has increased capping efficiency and viral gene expression, was
found to be significantly more resistant to type-I IFN treatment early during
infection compared to wild type SINV, with viral titer only being reduced by ~ 1 log
when IFN was added at 0 hpi (Fig. 3.5B). As with wild type SINV, the maximal titer
of the D355A mutant steadily increased as the addition of type-I IFN was delayed
to later times post infection; however, the relative differences in titer between the
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IFN treated infections and non-treated control indicate that the D355A mutant was
significantly more resistant to the impacts of type-I IFN overall. In contrast, the
N376A mutant, which has decreased capping efficiency, was found to have wildtype equivalent sensitivity to IFN when added at 0 and 1 hpi, but the N376A mutant
remained sensitive to the addition of type-I IFN at later times during infection
(Figure 3.5C). Surprisingly, even when IFN was added as late as 4hpi, the titers of
the N376A mutant remained decreased compared to those of the IFN negative
control, revealing that the N376A mutant remains sensitive to IFN for a longer
period of time than wild type SINV.
To enable the comparative analysis of the impact of type-I IFN on the viral
infections of the capping mutants compared to wild type infection, the differences
in viral titers between the IFN treated and the control infections for each virus and
time point were calculated. The differences in titer found for each nsP1 mutant
were then made relative to the corresponding differences observed for the wild
type infection (Fig. 3.5D). These data illustrate that during the early stages of viral
infection the D355A nsP1 mutant is approximately 2-fold more resistant to type-I
IFN than wild type SINV AR86; however, by 2 hpi the advantage has largely waned
and the level of IFN resistance is similar to that observed during wild type infection.
Similarly, comparing the resistance of the N376A mutant to wild type SINV AR86
further reveals that decreasing capping efficiency correlates with significantly
increased sensitivity to type-I IFN up to at least 4 hours post infection.
It is interesting to note that, in the absence of IFN treatment, infections of
the IFN-competent L929 cells with wild type SINV or the D355A mutant resulted in
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roughly equivalent viral titers at 24hpi. This is different than what was observed
previously in BHK-21 cells, where the D355A mutation resulted in significantly
decreased viral titer (Fig. 3.1D). This difference in phenotypes between the two
cell lines is likely due to the fact that the L929 cells are IFN competent and will
produce IFN in response to viral infection while BHK-21 cells are incapable of
doing so, resulting in differential viral replication rates due to the host response to
viral infection in conjunction with the apparent differences in IFN sensitivity.
Overall, the sensitivity of the SINV nsP1 mutants to IFN reflects the
differences seen in capping efficiency. Increased capping efficiency resulted in the
D355A mutant being more resistant to type-I IFN early during infection when
compared to wild type SINV. Likewise, decreased capping efficiency resulted in
the N376A mutant being more sensitive to type-I IFN. This indicates that both the
viral response to type-I IFN and the virus’ ability to mitigate the effects of IFN
expression on viral replication are altered depending on the level of ncgRNA
produced during infection.

Increasing Capping Efficiency Significantly Attenuates Neurotropic SINV In
A Mouse Model.
As the capacity to avoid the elicitation of the host innate immune response,
and the capacity to disregard the effects of the host type-I IFN response are vital
to alphaviral replication and pathogenesis, the above data suggested that altering
ncgRNA production could have profound effects on viral replication and
pathogenesis in vivo. We hypothesized that, due to the nsP1 D355A mutant’s
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increased resistance to type-I IFN and generally reduced activation of ISG
expression, mice infected with the nsP1 D355A mutant would experience disease
severity similar to wild-type SINV infection, perhaps with the mean survival time
being potentially decreased due to increased IFN resistance. Conversely, we
hypothesized that mice infected with the N376A mutant would experience more
mild disease and decreased mortality because of the mutant’s increased sensitivity
to IFN and the greater expression of ISGs in response to infection in tissue culture
models of infection. To test our hypothesis, we infected 4-week old male and
female C57BL/6 mice with 1,000 PFU of SINV AR86 wild-type, nsP1 D355A, or
nsP1 N376A via rear footpad subcutaneous inoculation. Mock infected mice were
inoculated with PBS in the same manner. When infected with wild type SINV, adult
C57BL/6 mice displayed significant weight loss as well as severe neurological
symptoms, including rapid onset paralysis of the limbs, blindness, and seizures at
approximately day 6 post infection (Figure 3.6A and B). Infection with wild type
SINV also led to significant mortality, with infected mice having a mean survival
time of ~6 days post infection (Figure 3.6C). Likewise, mice experimentally infected
with the decreased capping mutant N376A exhibited similar weight loss and
neurological symptoms as wild type infected mice. However, the onset of disease
in the N376A infected mice was delayed compared to wild-type SINV, with
neurological symptoms starting at 5 dpi and the mean survival time being ~7 dpi,
a full day later than what was seen with wild type SINV. In addition, a slightly
greater proportion of mice survived when infected with the N376A mutant as
opposed to wild type SINV. This increase in survival may be due to the delay in
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the N376A mutant to cause neurological symptoms, allowing the mice to be slightly
older, and therefore better able to resist severe, lethal encephalitis [80, 177, 178].
Surprisingly, the increased capping mutant virus D355A was significantly
attenuated in mice. Compared to the previous two viruses, mice infected with the
D355A mutant experienced minimal weight loss, milder neurological symptoms,
and significantly reduced mortality, with all but one mouse surviving to the end of
the study. Given that these mice did in fact show mild neurological and nonneurological symptoms and reduced weight gain compared to mock infected mice,
we concluded that the nsP1 D355A increased capping mutant virus is indeed
capable of causing pathogenesis, although the severity of disease is significantly
reduced compared to wild type infection.
The trends seen in morbidity and mortality between the mice infected with
wild type SINV versus the capping mutants were further reflected in H&E stained
sections of the brains of infected and uninfected mice (Figure 3.7). The brain
sections of both wild type and N376A infected mice displayed numerous lesions
consisting of lymphocytic meningitis; perivascular cuffing, which is indicative of
immune cell infiltration; and neuronal apoptosis, which left open pockets in the
tissue (Figure 3.7A). In addition, mice infected with either wild type SINV or the
N376A mutant had significant pathology in terms of inflammation, neuronal
degradation, and glial cell proliferation in multiple areas of the brain. Pathology
was highest in the cerebrum and the midbrain / brainstem, but lesions were also
found in the hippocampus and medulla oblongata of some mice (Figure 3.7B).
Conversely, the brains of the D355A infected mice resembled mock infected mice,
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with no immune infiltration, cell death, or other signs of pathology in any area of
the brain. Given that viral killing of neurons is the speculated cause of encephalitis
and paralysis in SINV infection, the differences in tissue damage and neuron death
seen between the D355A mutant and the other two viruses were not unexpected,
as the D355A infected mice did not exhibit signs of encephalitis or limb paralysis
(Figure 3.6B) [179, 180].
Collectively, these data suggest that modulating the production of ncgRNA
has significant impacts on alphaviral pathogenesis. Overall, the nsP1 N376A point
mutation, which increased ncgRNA production through decreased capping
efficiency, resulted in delayed disease progression and mortality compared to wild
type SINV in vivo. However, severity of neurological symptoms and pathology in
the brain were unaffected. In contrast, the nsP1 D355A point mutation, which
decreased ncgRNA production through increased capping efficiency, resulted in
significantly decreased mortality, mild neurological symptoms, and little to no
pathology in the brain. While the presence of mild symptoms and a lack of weight
gain in the D355A infected mice do suggest that the virus was capable of trafficking
to the brain and replicating, these data do not eliminate these as being possible
reasons for the decreases in pathogenesis seen thus far.

Attenuation Of Viral Pathogenesis Is Not Due To Deficits In Viral
Dissemination Or Replication.
Given that the D355A and N376A nsP1 mutants showed decreased viral
titers in tissue culture model systems compared to wild type SINV (Figure 3.1D),
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we hypothesized that the reduction in mortality seen in Figure 3.6 was due to poor
viral replication, dissemination, or a change in virus tropism for the brain. In order
determine the impact of modulating capping efficiency on viral replication and to
confirm that the nsP1 D355A mutant did in fact make it to the brains of infected
mice, we measured viral titer at the site of inoculation and in the serum at 1dpi as
well as in the brain at 7dpi. By comparing the viral titers of the nsP1 D355A mutant
to wild type SINV in these tissues, we were able to determine if decreasing
ncgRNA production impacts viral pathogenesis by altering viral replication,
dissemination, or tropism to the brain. If the D355A mutant had defective
dissemination or tropism to the brain, then we would expect to see wild type titers
at the site of inoculation, as well as potentially the serum, but an absence of viral
titer in the brain. Alternatively, if viral titers for the D355A mutant are significantly
decreased in the ankle, serum, and brain, then this would suggest that the
decreases seen in pathogenesis were due to poor viral replication and
dissemination.
Surprisingly, in contrast to what was expected given our tissue culture data,
viral titers in the ankle, serum, and brain were more or less equivalent between
wild type SINV and the two nsP1 mutants (Figure 3.8). The similar titers found in
the ankle between the nsP1 mutants and wild type SINV show that the reduced
pathogenicity of the nsP1 D355A mutant is not due to a defect in viral replication
at the site of inoculation (Fig. 3.8A). Likewise, since the nsP1 D355A mutant had
titers equivalent to wild type levels in the serum, we can also conclude that viral
dissemination was not negatively impacted (Fig. 3.8B). Finally, while the viral titer
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of the D355A and N376A mutant were both slightly decreased in the brain
compared to wild type SINV, the lack of a significant difference indicates that
increasing capping efficiency did not alter viral tropism to the CNS and that there
is no overt defect in viral replication (Fig. 3.8C). Interestingly, while these results
are different from what was previously observed during infection of BHK-21 cells
(Figure 3.1D), the trends seen in the serum and brain, where the N376A mutant
has slightly decreased viral titer compared to wild type SINV and the D355A
mutant, was similar to what was seen with the L929 cells (Figure 3.5).
To further complement our observations regarding the induction of the host
innate immune response to infection (as in Figure 3.4A), we quantitatively
assessed IFNβ transcript levels in the ankles of the experimentally infected mice
at 24hpi. Despite differences in the overall magnitudes of type-I IFN induction, we
found no differences between our in vitro and in vivo assessments (Supplemental
Figure 3.1).
The dissemination of the SINV mutants to the brain was further confirmed
when viral RNA levels in the brain were measured (Figure 3.8D). While the nsP1
D355A mutant did exhibit slightly lower vRNA abundance in the brain compared to
wild type SINV, it was not found to be a statistically significant difference and is
likely an artifact due to differences in when the brain tissue was collected. While
the majority of the D355A infected mice survived to 7 dpi when the brain tissue
was collected, all of the wild type infected mice met endpoint criteria prior to 7dpi.
As such, the adaptive immune response in the D355A infected mice that survived
to 7 dpi may have started to clear some of the infected cells serving as viral RNA
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reservoirs from the brain, resulting in the decreased vRNA abundance compared
to the wild type infected mice that did not survive long enough to mount a similar
response. N376A RNA levels in the brain were also found to be equivalent to that
of wild type SINV. These results indicate that, while the D355A and N376A nsP1
point mutations were capable of reducing viral titer in tissue culture, they were not
detrimental to viral replication in mouse models of infection.
Taken together, these data suggest that both the increased capping virus
D355A and the decreased capping virus N376A were capable of trafficking to the
brain from the site of inoculation, and were capable of replicating to high titers
within the brains of experimentally infected adult mice. It is also interesting to note
that neither viral titer nor viral genomic RNA abundance correlated with death, as
there were multiple mice which survived infection that had greater viral titer and
vRNA abundance in the brain than mice which died. Overall, these results led us
to conclude that the attenuation of pathogenesis seen in the D355A mutant were
not due to either deficits in viral replication or tropism.

Increasing Capping Efficiency Does Not Affect Viral Induction Of Neuronal
Apoptosis.
Since we did not find any significant differences in viral replication or tissue
tropism / dissemination, we next determined if decreased mortality in the D355A
mutant was due to an altered capacity to induce neuronal death, as virally induced
apoptosis of neurons in the brain, brainstem, and spinal cord have been shown to
be responsible for the severe neurological symptoms that arise during SINV
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infection [89, 179-181]. In addition, our previous study characterizing the nsp1
capping mutants in tissue culture showed that both the D355A and N376A mutant
demonstrated increased cell viability in BHK cells compared to wild type SINV,
supporting the possibility that the D355A mutant might have differences in cell
viability in neurons as well [171]. In light of our previous study as well as the striking
difference in cell death between the D355A and wild type infected brains (Figure
3.7), we hypothesized that increasing capping efficiency would decrease the virus’
capacity to kill neurons. To test this hypothesis, we infected SK-N-BE(2) cells with
either wild type SINV or one of the capping mutants and determined cell viability
24 hours after infection using ethidium bromide and acridine orange staining.
Infection with the decreased capping N376A mutant resulted in significantly greater
cell viability compared to either wild type SINV or the D355A mutant, which both
exhibited roughly similar levels of cell death (Figure 3.9). Interestingly, these
results suggest that increasing ncgRNA production leads to increased cell survival
in tissue culture models of infection, while decreasing ncgRNA production does
not seem to impact the virus’ capacity to kill neurons in tissue culture models of
infection. Given this, we can conclude that the differences seen in tissue damage
between the D355A and wild-type SINV infections in Figure 3.7 are not solely due
to deficits in the D355A mutant’s capacity to kill neurons. Instead, the above results
suggest that the neuronal death seen during SINV infection in mice may be largely
due to the host antiviral inflammatory response rather than direct cell death due to
infection.
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Differential ncgRNA Expression Alters The Immune Response To Infection.
Because the differences in morbidity and mortality between the D355A
nsP1 mutant and wild type SINV infected mice could not be explained by
reductions of viral titer or the capacity to induce neuronal death, we next
questioned whether differences in pathogenesis could be due to an altered host
immune response. Given the reduced immune infiltration and inflammation seen
in the D355A infected mice compared to the wild type or N376A infected mice
(Figure 3.7), we expected infection with the D355A mutant to also result in the
decreased expression of pro-inflammatory genes. To survey the immune response
to SINV nsp1 mutant virus infections, RNA was isolated from whole brain
homogenates of infected mice at 7 dpi or upon meeting endpoint criteria, and the
level of select cytokine and chemokine transcripts were measured via a qRT-PCR
based array. Out of the transcripts measured, 50 were found to be significantly
increased in wild type infected versus mock infected mice (Figure 3.10A). When
wild type and D355A infections were compared, we found 15 inflammatory
cytokines and chemokines whose expression was determined to be significantly
decreased (using a Benjamini-Hochberg corrected p-Value) by a magnitude
greater than 2-fold (Figure 3.10B). Individual box and whisker plots of these
statistically significant transcripts may be found in Fig. 3.10C. These included
chemokines involved in recruiting innate immune cells, such as CCL2, CCL3, and
CXCL10, as well as important drivers of inflammation like IFNβ, IL1β, TNFα. In
particular, the expression of CCL2 and CCL3 have been highly correlated with
areas of the brain experiencing high levels of gliosis and apoptosis, which is
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consistent with the differences in pathology scoring in those areas between the
D355A mutant and wild type SINV (Figure 3.7B) [182]. Interestingly, several of the
proteins that had decreased expression in the D355A infected mice compared to
wild type infected mice where identified by gene ontology as being part of the
extrinsic apoptotic pathway [183, 184]. The identification of proteins involved in
apoptosis, specifically Fas, Il1α, Il1β, and TNFα, is consistent with the significant
decrease in neuronal apoptosis seen in the H&E stained sections of mice infected
with the D355A mutant. Surprisingly, IFNγ expression, which has been previously
shown to be important for noncytolytic clearance of virus from neuronal cells, was
not found to be significantly different in either mutant compared to wild type (Figure
3.10A) [185].

As expected, the decreases seen in the expression of these

chemokines and pro-inflammatory cytokines are consistent with the reduced
immune infiltration and tissue damage seen in Figure 3.7.
Overall, these data show that the D355A increased capping mutant has
significantly reduced pathogenicity in a wild type mouse model of infection
correlating with decreased expression of multiple pro-inflammatory molecules at
the transcriptional level. Furthermore, the above data suggests that it is likely the
host response rather than viral replication per se that determines the extent of
alphaviral pathogenesis. This is supported by the finding that the wild type and
D355A viruses both had roughly equivalent viral titers in the brain, yet wild type
SINV had significantly increased pro-inflammatory cytokine transcript expression
compared to the D355A mutant. While transcript levels are not synonymous with
protein levels, the correlation between the expression of antiviral transcripts and

118

levels of inflammation in the brain suggest that antiviral protein expression likely
follows the same trends. Taken together, it can be concluded that decreased
ncgRNA production via increased capping efficiency leads to an altered host
immune response, which in turn shapes alphaviral pathogenicity.

Discussion
Altering Capping Efficiency Changes Viral Sensitivity To And Activation Of
Host Type-I IFN.
For Sindbis virus, the sensitivity of the virus to type-I IFN is largely
dependent on the translation of the nonstructural proteins which are responsible
for interfering with the IFN signaling pathway and for shutting down host
transcription [174, 186-188]. When capping efficiency was increased with the
D355A mutant, nonstructural gene expression was also found to be increased,
although the magnitude was not as drastic as was previously seen with the
Toto1101-derived background (Figure 3.2). However, this may not be necessarily
representative of what happens early during viral infection where the magnitude of
effect is likely to be more pronounced.

While we were previously able to

characterize early viral translation in the Toto1101-derived background using a
nanoluciferase reporter incorporated into nsP3, the construction of the identical
reporter in the AR86 background resulted in significant attenuation. However,
given that we have previously shown that the differences in viral translation for the
D355A mutant were more pronounced early during infection, and that increasing
capping was correlated with increased genomic translation in both viral
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backgrounds (Fig. 3.2C), it is likely that the D355A mutant in the AR86 background
would also follow this trend [171]. Increased translation of the viral proteins would
allow the virus to more quickly shut down IFN signaling pathways, host PAMP
sensors, as well as host transcription and translation, which would explain why the
D355A mutant showed reduced IFNβ and ISG expression and greater resistance
to IFNβ treatment [175, 189-191]. In addition, the altered IFNβ and ISG expression
seen with the capping mutant likely reflects changes in the virus’ abilities to both
avoid detection by the host as well as suppress the cellular antiviral response
[186]. Because IFNβ and ISG transcript abundance was normalized to viral RNA
levels, we know that the differences seen in antiviral transcript expression are not
simply due to differences in viral replication or the amount of vRNA present.
Rather, the changes observed in IFNβ and ISG expression for the D355A and
N376A nsP1 mutants are likely due to both differences in PAMP production and
their abilities to shutoff host transcription and translation. This is supported by the
correlation between ncgRNA production, which are a viral PAMP, and IFNβ/ISG
expression (Fig. 3.1B and Fig. 3.4) [189, 190]. Also, the fact that the D355A mutant
showed increased resistance to type-I IFN even when IFN was added concurrently
with the virus demonstrates how increasing capping efficiency allows the virus to
more readily mitigate the effects of the IFN response. The D355A mutant’s
increased resistance to IFN at such an early timepoint suggests that, in addition to
increased translation, the mutation may also affect how quickly the virus
progresses through the viral life cycle. Increasing the production of capped
genomic vRNA could potentially give the virus a head start on translation of the
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viral proteins responsible for shutting down the host IFN response, allowing the
D355A mutant to be more resistant to IFN treatment early during infection.

Noncapped Genomic vRNAs Are Critical For SINV Pathogenesis In Mice.
The ability to resist and shut down the type I IFN response has been shown
to be one of the major determinants of virulence for SINV. For example, the AR86
strain of SINV is a virulent strain known to efficiently suppress the type I IFN
response and cause lethal neurotropic disease in adult mice. The genetically
similar Girdwood strain only partially inhibits the type I IFN response, and thus is
avirulent in adult mice [101]. Given the above finding that the D355A mutant was
both more resistant to type I IFN treatment and resulted in decreased ISG
production compared to wild type virus, we were surprised to find that this mutant
did not cause severe disease or mortality in mice. Equally surprising was the result
that infection with the N376A mutant was similarly as severe and lethal as infection
with wild type SINV, despite N376A being more sensitive to IFN treatment and
stimulating more ISG expression in vitro. Taken together, this suggests that there
may be a balance between inhibiting and activating the IFN response which results
in pathogenesis, and that tipping the scales too far in either direction causes the
virus to become avirulent. Furthermore, our results indicate that ncgRNA play a
critical role in determining whether the virus is neurovirulent or avirulent, as
decreasing ncgRNA production with the D355A mutation resulted in significant
decreases in morbidity and mortality while increasing ncgRNA production with the
N376A mutation resulted in fully neurovirulent virus and lethal disease.
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Although the D355A mutation had a much more striking impact on morbidity
and mortality, the N376A mutation also had noticeable impacts on alphaviral
pathogenesis, namely a delay in the onset of symptoms, an increased mean
survival time, and a moderate increase in overall survival compared to wild type
SINV. The idea that inhibiting capping efficiency is detrimental to alphaviral
infection is not novel and multiple compounds and drugs have been developed to
specifically target nsP1 capping activity [166-169]. Our results do not negate the
idea that decreasing or inhibiting capping efficiency is an effective means of
combating alphaviral infection, but rather suggest that there is a threshold which
needs to be reached before decreasing capping efficiency will be significantly
detrimental to viral pathogenesis. Likewise, our mortality studies imply that the
virus is much more sensitive to increasing capping efficiency and that this novel
approach may be more effective in limiting the severity of viral disease.
During SINV infection, the development of severe encephalitis which leads
to paralysis and death is caused by the extensive apoptosis and necrosis of
neurons in the brain and CNS, which is believed to be virally induced [86, 179,
181, 192]. While apoptosis is the fate of many infected cells and neurons, a
significant portion of uninfected neurons are killed during viral infection due to
glutamate excitotoxicity [87]. The lack of apoptosis and necrosis seen in the brains
of mice infected with the D355A mutant (Fig. 3.7) suggests that, during in vivo
infection, decreasing ncgRNA production by increasing nsP1 capping efficiency
leads to decreased viral induction of neuronal apoptosis and therefore decreased
glutamate release, resulting in the reduced death of infected and uninfected
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neurons. However, when tested in tissue culture cells, infection with the nsP1
D355A mutant resulted in wild type levels of neuronal death, while infection with
the N376A mutant, which showed extensive signs of neuronal apoptosis and
necrosis in vivo, resulted in significantly increased neuron survival. Since
increasing capping efficiency did not seem to impact the virus’ ability to induce
neuron death in tissue culture, these data suggest that the apoptosis and necrosis
of neurons seen in the brain during SINV infection is largely mediated by an
external force, such as by the host immune response. This is supported by
previous studies which propose that the majority of neuronal death due to
apoptosis and glutamate excitotoxicity may be the work of T cells and astrocytes,
rather than being directly virus-induced [193, 194].
Another surprising result was that disease severity did not correlate with
increased viral titer or vRNA abundance. This is most clearly seen in the N376A
infected mice, where the viral titers and vRNA levels in the brains of mice that died
are interspersed among those which survived. In addition, surviving mice from both
the D355A and N376A infections had titers and vRNA levels in the brain that were
roughly equivalent to those found in the mice infected with wild type SINV which
died. Furthermore, neither viral titer nor vRNA burden in the brain correlated with
levels of inflammation seen in Figure 3.7. This suggests that, during SINV infection,
high viral titer alone is not sufficient to cause severe disease in mice. In addition,
altering capping efficiency did not significantly impact viral replication,
dissemination, or tropism. This was illustrated by the roughly wild type-equivalent
titers found in the ankle, serum, and brain indicating that both of the capping
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mutants were able to efficiently replicate at the site of inoculation, disseminate into
the blood, and traffic to the brain. However, the slight decrease in N376A titer seen
in the blood and brain does potentially suggest that dissemination may be slightly
delayed or impaired when capping efficiency is decreased, and may explain the
slight increase seen in mean survival time.
Unfortunately, one question we were unable to answer in this study was
whether viral capping efficiency in brain tissue was similarly affected by the nsP1
mutations, as was previously shown in tissue culture model systems and with
recombinant proteins [124, 171]. Regrettably, the limitations in sensitivity of
previously established and currently available assays render us unable to directly
answer this question, as these methods require a significant quantity of highquality viral RNA that is difficult to obtain from brain tissue. This is likely due to the
fact that an exceptionally few number of cells in the brain are required to be
infected for the manifestation of significant disease and the appearance of
endpoint criteria. However, the altered pathogenesis seen in mice in the absence
of any obvious defects in viral replication, dissemination, or tropism lead us to
believe that the point mutations incorporated are still altering capping efficiency
and are not significantly affecting nsP functions in other ways. Previously
characterized mutations in nsP1 which resulted in loss of neurovirulence did so by
significantly altering vRNA synthesis and/or processing of the nonstructural
polyprotein, which typically resulted in decreased viral titer in animal models of
infection [100, 101, 170, 195]. Given that neither the D355A nor N376A mutations
significantly altered viral titer or vRNA burden during SINV infection in vivo, nor
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negatively impacted vRNA synthesis or viral translation in vitro , we can conclude
that the phenotypes seen both in tissue culture and in animal models of infection
are the result of the mutations altering ncgRNA production through modulating
capping efficiency. Furthermore, given the conserved effect of the D355A and
N376A nsP1 point mutations in multiple alphaviruses in tissue culture and in vitro,
it is likely that these mutations still respectively increase or decrease capping
efficiency in vivo, but the magnitude that capping efficiency is altered may be
different from what was previously seen in tissue culture [124, 171].

Noncapped Genomic RNAs Determine SINV Virulence by Modulating the
Host Inflammatory Response.
Infection with the D355A capping mutant resulted in the decreased
expression of multiple cytokines and chemokines associated with the recruitment
of immune cells, regulating inflammation, and apoptosis. While there were a small
number of cytokines found to be differentially expressed during infection with the
N376A mutant compared to wild type SINV, they did not implicate any pathways
in particular. Interestingly, expression of anti-inflammatory transcripts such as
TGFβ and IL-10 was found to be similar between D355A and wild type infection,
while others such as SOCS1 were found to be significantly decreased. This
suggests that the decreased inflammation seen with the D355A mutant is due to
decreased activation of antiviral and inflammatory pathways rather than increased
expression of anti-inflammatory cytokines. The decreased activation of these
antiviral pathways are likely due to both the reduced release of DAMPS from dying
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cells and decreased sensing of viral PAMPS. The first is supported by the
identification of several of the affected proteins being involved in apoptosis as well
as the decreased level of cell death seen with the D355A mutant. The second is
supported by the decreased IFNβ and ISG expression seen during D355A infection
(Figure 3.4). The decreased sensing of viral PAMPS may be due to the D355A
mutant either being more efficient at inhibiting the cell’s viral sensors and signaling
pathways through shutoff of host transcription or could be due to the D355A mutant
producing fewer noncapped RNA, which are an established PAMP [189, 190].
Given that viral infection in animals is a continuous process, shut-off of cellular
transcription and suppression of the IFN response in tissues likely does not occur
as efficiently or completely as it does in cell culture, where all the cells are infected
simultaneously. Therefore, the decreased production of inflammatory cytokines
seen with the D355A mutant is likely due to reduced detection of DAMPs and
PAMPs caused by decreased cell death and decreased production of ncgRNA.
How exactly the ncgRNA are sensed by the host during viral infection is not
currently known and is an ongoing interest in the Sokoloski lab. While there is
some evidence that suggests that the noncapped RNA produced during alphaviral
infection are at least in part sensed by RIG-I, it is unknown if this is also true for
ncgRNA and there may be additional methods for detecting noncapped vRNA that
have yet to be characterized [190, 196]. Overall, the correlation between
decreased inflammation and decreased ncgRNA production leads us to conclude
that the ncgRNA play a critical role in determining the host response to viral
infection.
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In conclusion, we have identified a novel determinant of Sindbis virulence
which operates through a separate mechanism than those previously described.
Specifically, decreasing the production of ncgRNA by increasing capping efficiency
results in the loss of neurovirulence which we believe is due to the reduced
production of RNA PAMPs that would otherwise cause excess inflammation and
wide-spread cell death in the brain (Fig. 3.11). The D355A mutation differs from
previously identified nsP1 virulence determinants in that it does not negatively
affect viral titer nor resistance to IFN, such as is seen with the SINV nsP1 cleavage
mutant T538I and the 6 nsP1 mutations characterized in Ross River virus [97, 170].
The D355 residue in nsP1 is also unique from the aforementioned mutation sites
in that it is very highly conserved among SINV strains as well as across both the
old and new world alphaviruses. While the results of this paper indicate that the
production of ncgRNA is critical to SINV pathogenesis, more work is needed to
further characterize the mechanisms by which ncgRNA contribute to alphaviral
neurovirulence.
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Figure 3.1. Point mutations in nsP1 of AR86 SINV result in changes in
capping efficiency and negatively impacts infection in mammalian cells. (A)
Quantitative assessment of SINV RNAs produced during infection of BHK-21
cells with either wild type SINV or either of the nsP1 mutants at an MOI of 5
PFU/cell. RNA was collected at 16hpi and treated as described in Materials and
Methods. Graphs depicting the relative quantities of noncapped (B) or capped
(C) genomic RNAs produced during infection of BHK-21 cells with either wild
type SINV or either of the nsP1 mutants at 16hpi. (D)One-step growth kinetics of
the individual capping mutants and the parental wild-type SINV in BHK-21 cells
infected at an MOI of 5 PFU/cell. All the quantitative data shown represent
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means of results from three independent biological replicates, with error bars
representing standard deviation of the means. Statistical significance was
determined by analysis of the area under the curve. *=p<0.05. **=p<0.01.
***=p<0.001. ****=p<0.0001.
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Figure 3.2. Increasing capping efficiency increases translation of SINV
AR86 nonstructural polyprotein. (A) BHK-21 cells were infected with either
wild type SINV or one of the nsP1 capping mutants at an MOI of 5 PFU/cell.
Abundance of nsP2 was then assessed at 8hpi by Western blotting.
Nonstructural polyprotein band marked by ▲. The p23 polyprotein intermediate
band (as determined by molecular weight) is marked by

. Fully processed nsP2

band marked by ●. Actin is shown as the loading control. Densitometric
quantification of fully processed nsP2 protein (B), nonstructural polyprotein (C),
and total nsP2 signal (D) normalized to actin levels at 8hpi. All the quantitative
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data shown represent means of results from three independent biological
replicates, with error bars representing standard deviation of the means.
Statistical significance was determined using Student’s t-test.
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Figure 3.3. Altering capping efficiency does not impact AR86 SINV vRNA
synthesis. BHK-21 cells were infected with either wild type SINV or one of the
nsP1 capping mutants at an MOI of 5 PFU/cell. Absolute quantities of the genomic,
subgenomic, and minus strand vRNAs produced at 4 (A), 8 (B), and 16hpi (C) were
determined by qRT-PCR. All the quantitative data shown represent means of
results from three independent biological replicates, with error bars representing
standard deviation of the means. Statistical significance was determined using
Student’s t-test.
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Figure 3.4. Production of type-I interferon and ISGs in response to SINV
nsP1 capping mutants. L929 cells were infected at an MOI of 10 PFU/Cell with
either wild-type SINV or an individual capping mutant. Cell lysates were collected
at 6, 8, 16, and 24hpi and transcript expression levels for IFNβ (A) and the
selected ISGs (B-E) were determined by qRT-PCR for their respective times post
infection. Data was normalized to GAPDH and nsP1 and calculated relative to
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uninfected controls. All the quantitative data shown represent means of results
from three independent biological replicates, with error bars representing
standard deviation of the means. Statistical significance was determined by
Student’s t test.
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Figure 3.5. Analysis of SINV sensitivity to type-I interferon. L929 cells were
infected with either wild-type SINV or an individual capping mutant at an MOI of 10
PFU/cell. At the indicated times post infection, 20 IU of recombinant Type-I IFN
was added to the growth medium and the cells were incubated for a period of 24
hours. (A-C) Viral titers were quantified via plaque assay, and (D) the relative
sensitivity of the viruses was determined by comparing their growth relative to
untreated controls. All the quantitative data shown represent means of results from
three independent biological replicates, with error bars representing standard
deviation of the means. Statistical significance was determined by Student’s t test.
*=p<0.05. **=p<0.01.
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Figure 3.6. Increased vRNA capping efficiency reduces SINV AR86 mortality
and pathogenesis. 4-week old male and female C57BL/6J mice were either mock
infected or infected with 1,000 PFU of SINV AR86 wild-type , D355A , or N376A
via rear footpad subcutaneous inoculation. Each data point represents a single
animal from either experimental replicates. The experimentally infected mice were
assessed over a 14 day period. (A) Animals were weighed twice daily. Weights are
shown relative to initial weight after being infected. (B) Mice were scored based on
a 1-5 scale for neurological response. (C) Kaplan-Meier analysis indicates the WT
median survival time (MST) at ~6.4 days and the N376A mutant MST at ~7 days.
The P values indicated on the figure were determined by the Log-rank test.
*=p<0.05, ****=p<0.0001. Data shown were pooled from 2 independent
experiments with an n of at least 16 per experiment.
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Figure 3.7. Increased capping efficiency leads to decreased pathology in the
brain. A) Representative H&E stained sagittal sections of the midbrain (20x
magnification) from mock, wild-type, or capping mutant infected mice at 7dpi or at
the time at which end point criteria was met. The brains of SINV wild-type and
N376A infected mice show large amounts of perivascular cuffing, immune
infiltration, and cell death not present in the mock and D355A infected mice. Scale
bar = 0.1mm. B) Ranked pathology scoring of indicated sections of the brain from
infected mice. Data points indicate scoring for each experimental animal,
representing at least 5 biological replicates.
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Figure 3.8. Viral replication is largely unaffected by altered capping in vivo.
(A-C) Tissues were harvested at the indicated times post infection and viral titer
was determined via plaque assay. (D) Viral genomes were measured by qRTPCR. The data points indicate the individual titers for each experimental animal,
and the mean values shown are the geometric means of at least four biological
replicates from two independent experiments, with the error bars representing the
geometric standard deviations of the means. ▲= mice that met endpoint criteria
prior to day 7. Statistical significance was determined using Student’s t test.
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Figure 3.9. Neuron viability increased with decreased capping efficiency. SKN-BE(2) neurons were infected at an MOI of 30 PFU/Cell with either wild-type SINV
or an individual capping mutant. Cell viability was determined at 24hpi using
ethidium bromide/ acridine orange staining and is represented as the proportion of
viable cells out of total cells counted. A minimum of 100 total cells per well were
counted using ImageJ. All the quantitative data shown represent means of results
from three independent biological replicates, with error bars representing standard
deviation of the means. Statistical significance was determined by Student’s t test.
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Figure 3.10. Increased viral capping efficiency results in reduced expression
of pro-inflammatory genes in the brain. (A) Cytokine transcript levels in the brain
at 7dpi were measured by qRT-PCR. Data was normalized to GAPDH and
calculated relative to uninfected controls. (B) Volcano plot showing the fold change
in transcript expression between wild type SINV and the D355A mutant. Green
points are transcripts that have greater than a 2-fold change in expression and are
significant according to the Benjamini and Hochberg corrected p value. (C)
Cytokines and chemokines whose expression was significantly increased
compared to uninfected controls and exhibited a significant difference in
expression between wild type SINV and the D355A mutant that was greater than
2-fold. All the quantitative data shown represent means of results from at least
three independent biological replicates, with center lines representing the median,
+ representing the mean, boxes representing the interquartile range, error bars
representing standard deviation of the means, and • representing outliers as
determined by Tukey’s method. Statistical significance was determined by
Student’s t test.
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Figure 3.11. Proposed model of how increasing genomic vRNA capping
negatively impacts viral pathogenesis. Infection of the brain with the
decreased capping nsP1 mutant N376A results in increased production of
ncgRNA , which likely act as PAMPs (left). The increased levels of PAMPs in the
brain results in increased activation of the immune response, leading to
excessive neuroinflammation and neuropathology. Conversely, infection of the
brain with the increased capping nsP1 mutant D355A results in decreased
production of ncgRNA, and therefore decreased production of PAMPs (right).
The decreased levels of PAMPs results in a more moderate immune response
that leads to neuroprotection and survival.
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Supplemental Figure 3.1. Quantitative Analysis of IFNβ Transcript Levels in
SINV AR86 Infected Ankle Tissue. Ankle tissues harvested from either mock
infected, wild type SINV AR86, or SINV AR86 nsP1 mutant infected animals were
harvested at 1 day post infection and homogenized. Total cellular RNA was
isolated from the tissue homogenates and assessed via qRT-PCR to determine
the relative transcript abundances of the IFNβ gene. Quantitative data shown are
the means of at least three biological replicates, with the error bars representing
the standard deviation of the means. Statistical analysis of the data, as by
Student’s T-Test, indicated no significant differences between the SINV AR86
infected tissues in regards to IFNβ transcript levels.
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Supplemental Table 3-1. Primers used in this study.
Linker= F: GTTCAGAGTTCTACAGTCCGACCCATC
SINVg.CapAssay= R: CGTCTACGTTTACTACTGGCTTCTCC
SINV.nsP1 =F: AAGGATCTCCGGACCGTA,
R: AACATGAACTGGGTGGTGTCGAAG
SINV.E1= F: TCAGATGCACCACTGGTCTCAACA,
R: ATTGACCTTCGCGGTCGGATACAT
Mam.18S= F: CGCGGTTCTATTTTGTTGGT,
R: AGTCGGCATCGTTTATGGTC
IFIT2= F: AGTACAACGAGTAAGGAGTCACT,
R: AGGCCAGTATGTTGCACATGG
SHB= F: CTGATGACTACTCCGATCCCTT,
R: GGGGTGTCGTACAACTGGATG
CXCL10= F: CCAAGTGCTGCCGTCATTTTC,
R: GGCTCGCAGGGATGATTTCAA
IFIH1= F: AGATCAACACCTGTGGTAACACC,
R: CTCTAGGGCCTCCACGAACA
Viperin= F: TGCTGGCTGAGAATAGCATTAGG,
R: GCTGAGTGCTGTTCCCATCT
MX2= F: GAGGCTCTTCAGAATGAGCAAA,
R: CTCTGCGGTCAGTCTCTCT
OAS2= F: TTGAAGAGGAATACATGCGGAAG,
R: GGGTCTGCATTACTGGCACTT
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BST2= F: TGTTCGGGGTTACCTTAGTCA,
R: GCAGGAGTTTGCCTGTGTCT
IFNβ= F: AAGAGTTACACTGCCTTTGCCATC,
R: CACTGTCTGCTGGTGGAGTTCATC
GAPDH= F: AGGTCGGTGTGAACGGATTTG,
R: TGTAGACCATGTAGTTGAGGTCA
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CHAPTER 4
DISCUSSION AND FUTURE DIRECTIONS

Research Summary
Although the production and prevalence of the noncapped genomic RNA
(ncgRNA) during alphaviral infection had been previously established, prior to
these efforts, very little was known about their importance to viral infection and
pathogenesis. By using mutations whose impacts on nsP1 enzymatic activity had
been previously established in a similar virus outside of the context of infection
using recombinant nsP1 protein, we were able to show that the capping activity
of SINV nsP1 could be intentionally modulated during viral infection [124]. By
altering the capping efficiency of nsP1 through the use of these point mutations,
we were able to show that decreasing ncgRNA production negatively impacts
viral infection. In characterizing these nsP1 capping mutants, we revealed that
the decreased viral growth kinetics caused by decreasing ncgRNA production
was not due to decreases in viral translation or vRNA synthesis, but rather was
due to deficits in particle production. This marks the first time that the RNA
capping activity of nsP1 has been directly implicated in determining particle
production in any of the alphaviruses, outside of nsP1 mutations which altered
production of viral proteins or vRNA synthesis. Furthermore, our results indicate
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that the ncgRNA specifically play an important role in regulating viral particle
production.
In addition to the described impacts on viral infection in vitro, our data also
establishes that the ncgRNA are vital to alphaviral pathogenesis, as decreasing
ncgRNA production resulted in reduced morbidity and mortality as well as
decreased inflammation, immune infiltration, and cell death in the brain.
Altogether, this was found to be due to the decreased expression of inflammatory
cytokines in response to infection. While previous research with RRV had loosely
correlated changes in ncgRNA production with disease progression, we were
able to use the SINV nsP1 mutants to definitively show that the ncgRNA are
major determinants of alphaviral pathogenesis [97, 99]. Furthermore, while
ncgRNA had been previously found to be associated with activation of type-I IFN
at the cellular level, we were able to expand upon this and show how altering
ncgRNA production directly impacted activation of, as well as viral sensitivity to,
type-I IFN. We also demonstrated that the ncgRNA were important for
determining the host inflammatory response. Despite the wealth of evidentiary
data connecting ncgRNAs to pathogenesis via the host response, exactly how
the ncgRNA dictate disease severity and the host antiviral response is still
unknown.

Evolutionary Conservation of ncgRNA
Multiple alphaviruses have been shown to produce ncgRNA during
infection, indicating the ncgRNA production is conserved among the alphavirus
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genus. Since producing ncgRNA results in a greater immune response without
lending an obvious advantage to viral replication in regards to viral gene
expression or vRNA synthesis, there must be a separate reason for alphaviruses
to have conserved their production as they are translationally inert and incapable
of initiating infection by themselves. Our data suggests that alphaviruses may
have conserved ncgRNA production in order to more efficiently replicate at the
cellular level via the efficient production of viral particles. This is supported by the
data in Chapter 2, where we showed that increasing capping impairs particle
production in vitro. Nonetheless, in cellular models with an intact IFN response
system, and in adult mouse models of infection, viral titer was similar between
the D355A and wild type viruses (Chapter 3). It should be noted that in the IFNcompetent tissue culture model this was not due to increased infectious particle
production in the D355A mutant, rather the production of wild type virus was
reduced while D355A remained comparatively unaffected in regards to titer. We
postulate that the equivalency between the wild type and D355A mutant in this
scenario is due to the reduced induction of, and increased resistance to, type-I
IFN by the D355A mutant which resulted in a slight advantage over the wild type
virus despite decreased particle production. Similarly, although viral titer was not
significantly different between D355A and wild type SINV in mice, this doesn’t
necessarily mean that the D355A did not still experience a defect in particle
production in vivo, but rather could simply be explained as an effect of the D355A
mutant being more resistant to IFN. If the ncgRNA play an important role in
particle production in both in vitro and in vivo infections, then alphaviruses may
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have conserved ncgRNA production in order to more efficiently replicate at the
cellular level. This would be especially important in the context of the reservoir
host, where severe disease does not develop in response to wild type alphaviral
infection. In this case, the increased particle production and higher viral titer that
occurs when ncgRNA are present would be advantageous to the virus as it would
allow for better viral transmission.
A second possibility is that alphaviruses produce ncgRNA because they
are beneficial to viral transmission between the vertebrate host and invertebrate
vectors, and vice versa. Previous work has shown that mosquitos fed alphaviral
particles containing primarily capped genomic RNA have a significantly lower
midgut infection rate compared to those that were fed primarily ncgRNA
containing particles [123]. Furthermore, it has also been shown that, during
vertebrate infection, the particles found in the serum are those associated with
ncgRNA [123]. The fact that the particles containing mostly ncgRNA were also
more infectious in mosquito models of infection strongly suggests that the
ncgRNA are important for alphaviral transmission between the vertebrate host
and the invertebrate vector. It is also interesting to note that infection of
mosquitos using particles that contained primarily capped genomic RNA elicited
a significantly weaker immune response in the midgut compared to the particles
that contained mostly ncgRNA. The induction of an immune response in the
midgut by the ncgRNA may function to help disrupt the midgut barrier, allowing
for better dissemination of the virus throughout the mosquito. While more work
would need to be done to characterize the importance of the ncgRNA to
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invertebrate infection as a whole, this does suggest that the ncgRNA play a
critical role in establishing viral infection of the mosquito vector.

Role of ncgRNA in Particle Production
One particularly interesting finding that was described in Chapter 2 was
that decreasing ncgRNA production alone had a significant detrimental impact to
viral particle production. While it is unknown how the ncgRNA aid in viral particle
production, there are multiple scenarios where the ncgRNAs could affect particle
production.
One such scenario is that the ncgRNA bind a unique set of proteins that
allow them to manipulate the cellular environment in favor of particle production
(Fig. 4.1A). It stands to reason that if the capped genomic RNA are being
translated in a manner similar to host mRNA, in that the RNA is lined with
multiple ribosomes which all simultaneously translate the RNA, then the capped
genomic RNA are not going to be able to efficiently interact with viral or host
factors. In contrast, because the ncgRNA are not translated as they lack the
canonical cap structure, translating polysomes would not form. This would allow
the ncgRNAs to be available to interact with host/viral factors as well as maintain
any secondary RNA structures that may be required for protein or RNA
interaction [197]. Therefore, it is likely that the ncgRNA bind a different suite of
proteins than the capped vRNA. While this has not been shown for alphaviral
RNAs, the notion that non-translating RNAs bind different proteins than
translating RNAs has been shown for eukaryotic mRNAs, especially in regards to
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P-body formation and translational silencing [198, 199]. In relation to particle
production, this means that the ncgRNA may either recruit proteins necessary for
efficient particle production or sequester proteins which may inhibit particle
assembly away from the vRNA population as a whole. This would allow the
ncgRNA to mold the intracellular environment into one that is favorable for
efficient particle production. Thus, by decreasing ncgRNA production with the
D355A mutation, the virus’s capacity to form a pro-assembly environment may
have been reduced.
A second possibility is that the ncgRNA prevent premature disassembly of
the nucleocapsid during the assembly process (Fig. 4.1B). Following entry of the
viral particle into the host cell, the incoming nucleocapsid core is disassembled
by the binding of the 60S ribosomal subunit to the capsid protein [57]. Because
the capped genomic RNA are associated with polysome formation and
translation, there would be an abundance of 60S ribosomal subunits bound to
them or in close proximity. Once the virus begins assembling progeny particles,
continued association of the 60S ribosomal subunit with the genomic RNA could
potentially trigger premature disassembly of the nucleocapsid core before it can
be adjoined to the viral glycoproteins and released as a mature particle.
Therefore, it is likely that the nucleocapsid assembly microenvironment benefits
from being devoid of ribosomal components and translating RNAs. Because the
ncgRNA are not translated, they would not recruit the 60S ribosomal subunit, and
would not trigger premature disassembly of the viral capsid. Thus, it is possible
that the ncgRNA may serve as a buffer between the areas where viral translation
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and particle assembly occur. However, as we know that both capped RNA and
ncgRNA are packaged into viral particles and the packaging of capped vRNA is
essential for viral infection, the ncgRNA buffer between the translating capped
vRNA and the particle assembly area cannot by too restrictive, or no capped
vRNA would be packaged into particles. The purpose of the ncgRNA buffer zone
may then be to dilute the translating vRNA that are being packaged into particles,
effectively reducing the amount of 60S ribosomal subunit present in a
concentrated area, allowing for more efficient particle production.
Finally, the ncgRNA may act as allosteric effectors which aid in the
formation of the nucleocapsid core (Fig. 4.1C). While this has not been explicitly
shown for alphaviruses, the ability of viral RNA to allosterically regulate
nucleocapsid assembly has been demonstrated in Rous sarcoma virus as well as
bacteriophage MS2 [200]. In Rous sarcoma virus, particle assembly is inhibited
by intramolecular interactions between different domains of the capsid protein
Gag which prevent its dimerization. Binding of the viral RNA to Gag induces one
or more conformational transitions that allows the protein to dimerize and
assemble into a lattice structure [201]. In MS2, in addition to inducing capsid
assembly, the viral RNA is also thought to act as a scaffold that directs the
assembly of capsid proteins into the proper conformation for the viral particle
[202]. Given that the specifics of the alphaviral capsid assembly are not currently
known, it is possible that the ncgRNA may function as allosteric effectors that
dictate the efficient assembly of nucleocapsid cores [66]. Therefore, decreasing
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ncgRNA production may have resulted in the decreased presence of an effector
which may allow for efficient particle assembly.

Role of ncgRNA in Pathogenesis
A major finding of the in vivo characterization of the nsP1 mutants in
Chapter 3 was that decreasing ncgRNA production resulted in little to no
morbidity or mortality in mice. Interestingly, this was not due to defects in viral
replication or tissue tropism, but rather this phenomenon was largely due to
decreased expression of inflammatory molecules at the transcript level in the
brain. This indicates that the ncgRNA are determinants of disease severity and
that their presence plays a role in the activation / quality of the immune response.
While exactly how the ncgRNA determine the host inflammatory response is
unknown, it is likely to be at least in part due to the ncgRNA acting as PAMPs.
Due to its lack of a 5’ cap structure and likely increased secondary structure as
they are not translated, the ncgRNA would serve as PAMPs that could be
detected by multiple host innate immune proteins. As briefly stated in the
introduction, RIG-I is responsible for detecting noncapped RNA, specifically
RNAs with a 5’ di- or triphosphate [203]. While the vast majority of the ncgRNA
produced by SINV have a 5’ monophosphate which is undetected by RIG-I,
~20% of the ncgRNAs contain a 5’ di- or triphosphate, meaning that a small
portion of the ncgRNA can potentially be detected by RIG-I [99]. In addition to
being noncapped, the extensive branched secondary structures of ncgRNA may
also serve as a PAMP for detection by innate immunity. Because translation of

156

the RNA by ribosomes would result in the disruption of RNA secondary structure,
it is likely that the non-translating ncgRNA would have significantly more
secondary structure present than the capped genomic RNA, making the ncgRNA
a target for dsRNA sensors like MDA5 and LGP2 as well.
The specific importance of MDA5 vs RIG-I in detecting alphaviral infection
has not yet been firmly established; and in general seems to be dependent on
viral strain, cell type, and mouse background [114, 204, 205]. The variation seen
in the importance of RIG-I and MDA5 signaling to restricting viral infection may
be in part due to the two proteins activating distinct response pathways that may
be different or less prevalent depending on the context of infection. While there
has been some evidence for CHIKV that RIG-I and MDA5 are redundant, work
with flaviviruses has shown that they have unique roles in inducing expression of
innate immune genes [206-208]. Therefore, detection of the ncgRNA by either
one or both RIG-I and MDA5 may be responsible for the high levels of
inflammation seen with wild type SINV infection and may account for why
inflammation is reduced when ncgRNA production is decreased. However, more
work is required to determine which of these immune sensors are specifically
detecting the ncgRNA during alphaviral infection and to further establish that the
role of the ncgRNA as PAMPS is directly tied to disease severity in vivo.

ncgRNA as a Novel Antiviral Target
Given the importance of the 5’ cap to viral infection, it is unsurprising that
the alphaviral capping enzyme has been a target for antiviral research. There
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have been multiple compounds developed to inhibit nsP1 capping activity. Some
of these compounds directly interact with nsP1 to inhibit vRNA capping. For
instance, MADTP-314 is known to directly disrupt the GTPase activity of nsP1,
while FHA and FHNA were found to directly inhibit the MTase activity of nsP1
[166, 209]. Although the exact mechanisms by which these compounds inhibit
nsP1 is not known, they will likely become more clear in the near future now that
the structure of nsP1 has been determined. Other compounds disrupt nsP1
capping activity in a more indirect manner. Many of these, such as ribavirin, are
GTP analogs which can outcompete GTP for the nsP1 binding site and prevent
the capping reaction from occurring [168, 210]. Targeting SAM, which donates
the methyl group to make the cap, is another route which prevents RNA capping
that has been used for drug development [211]. Examples include Sinefungin, a
SAM analog which has been shown to be able to inhibit transmethylation and
disrupt nsP1 capping activity [212]. It is important to note that although many of
these drugs have been shown to significantly reduce alphaviral replication in
vitro, as of yet, none have been tested for efficacy against alphaviral infection in
vivo.
The success of the nsP1 capping mutants to significantly impact morbidity
and mortality in response to alphaviral infection highlights the ncgRNA as a novel
target for antiviral development. While the antiviral studies mentioned above all
focused on inhibiting nsP1 capping efficiency, which would result in increasing
ncgRNA production, we have shown that SINV is significantly more sensitive to
decreasing ncgRNA production than to equivalent increases in ncgRNA
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production. This was proven to be true for both viral replication at the molecular
level as well as disease progression as a whole. The fact that SINV was less
sensitive to decreases in capping activity is of particular interest in regards to the
above mentioned antivirals, since if they do not sufficiently inhibit capping in vivo,
they may not be efficacious. Furthermore, it is not known how increasing
ncgRNA production, and therefore PAMP production, partway through infection
may impact severity of disease, as treatment in the clinical setting often begins
after the manifestation of pathology. Therefore, despite the counterintuitive
approach of enhancing a viral replication process, decreasing ncgRNA
production may be a more viable option for the development of viable antiviral
therapies or preventatives than trying to reduce capped genomic RNA production
to the point that it negatively impacts the virus.

Future Directions
While the work shown here establishes the importance of the ncgRNA to
viral infection, there is still relatively little known about their specific functions
during viral infection and the mechanism by which they influence pathogenesis.
Therefore, future studies would endeavor to further characterize the ncgRNA and
their roles during alphaviral infection. As stated above, this would include
determining how ncgRNA influence particle production, identifying unique binding
partners, characterizing how they are detected by innate immune sensors, and
determining the potential of ncgRNA for the development of antivirals.
Additionally, while ncgRNA production has been experimentally shown for SINV
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and RRV, characterizing ncgRNA production in other alphaviruses such as
CHIKV or VEEV would help to establish their importance to alphaviral infection
as a whole. Given the highly conserved nature of nsP1, it is likely that the
inefficiency of 5’ capping seen with SINV is true of the other alphaviruses as well,
although the proportion of ncgRNA produced relative to capped genomic RNA
will likely differ. In addition, future work which determines how alphaviruses
evolve in response to mutations in nsP1 which alter capping efficiency,
specifically whether there are direct reversions or compensatory mutations in the
viral genome, may be able to shed further light on why ncgRNA production is
conserved among the alphaviruses.
Also, although the work described here establishes the importance of the
ncgRNA to alphaviral infection in mammals, how ncgRNA production affects
infection of invertebrates has yet to be determined. It will be particularly
interesting to see if altering ncgRNA production has a similar impact on viral
infection and the antiviral response in whole mosquito models of infection. Since
previous studies have shown that even altering the amount of ncgRNA present
during the initial round of viral replication has drastic impacts on mosquito
infection, maintaining these differences in ncgRNA production throughout the
course of infection with the D355A capping mutant will potentially result in even
greater deficits to viral infection.
Given the impact of altering ncgRNA production on disease severity,
another future direction would include assessing the potential of the D355A
mutant for vaccine development. While using the single point mutation by itself
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may not result in a viable vaccine due to the high likelihood of reversion,
development of a virus with multiple mutations which affect capping may yield
greater stability of the capping phenotype. A second approach would be to
incorporate the D355A mutation into an already existing vaccine strain, such as
VEEV TC83 and CHIKV 181/25, in order to reduce the high incidence of adverse
effects while maintaining a high level of protection.
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Figure 4.1. Potential roles for ncgRNA in alphaviral particle production. (A) Viral
RNA (red lines) may bind different host or viral factors depending on whether or not the
vRNA is capped. The ncgRNA may aid in particle assembly by recruiting proteins which
make particle assembly more efficient (in purple and blue), or sequestering proteins
which would impair particle assembly (in orange and green). (B) The 60S ribosomal
subunit (large yellow half circles) are known to trigger particle disassembly. Therefore,
having many translating capped vRNAs in the same area where particle assembly takes
162

place may lead to increased association of the 60S ribosomal subunit with viral capsid
(red triangles) and lead to premature disassembly of the particles (Left). In this case, a
potential function of the ncgRNA may be to serve as a buffer between the translating
vRNAs and areas of particle assembly to prevent premature particle disassembly
(Right). (C) Lastly, the ncgRNA may regulate particle assembly by acting as allosteric
effectors. Binding of the capsid protein to the ncgRNA may allow for easier initiation of
particle assembly. Additionally, the ncgRNA may act as a scaffold which direct proper
assembly of the capsid proteins.
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Abbreviation
ANOVA

Analysis of Variance

AUD

Alphavirus Unique Domain

Bax

Bcl-2 Associated X protein

Bcl-2

B-cell lymphoma 2

BHK

Baby hamster kidney cells

BST-2

Bone Marrow Stromal Cell Antigen 2

CCL2

C-C Motif Chemokine Ligand 2

CCL3

C-C Motif Chemokine Ligand 3

CHIKV

Chikungunya virus

CNS

Central nervous system

CXCL10

C-X-C Motif Chemokine Ligand 10

DAMP

Damage-associated molecular pattern

dpi

Days post infection

dsRNA

Double-stranded RNA

EB/AO

Ethidium bromide/ acridine orange

EEEV

Eastern Equine Encephalitis virus

ER

Endoplasmic reticulum

FBS

Fetal Bovine Serum
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GAPDH

Glyceraldehyde 3-phosphate dehydrogenase

GFP

Green Fluorescent Protein

H&E

Haematoxylin and eosin

hpi

Hours post infection

IFIH1

Interferon Induced With Helicase C Domain 1

IFIT1

Interferon Induced Protein With Tetratricopeptide
Repeats 1

IFN

Interferon

IFNAR

Interferon alpha/beta receptor

IL-1

Interleukin-1

IL-10

Interleukin-10

IRF

Interferon response factor

ISG

Interferon stimulated gene

IU

Infectious unit, International unit

JAK

Janus kinase

LGP2

Laboratory of Genetics and Physiology 2

MAVS

Mitochondrial antiviral-signaling protein

MCP-1

Monocyte chemoattractant protein 1

MDA5

Melanoma differentiation-associated protein 5

MEM

Minimal Essential Media

MOI

Multiplicity of Infection

mRNA

Messenger RNA

MX2

Myxovirus Resistance Protein 2
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ncgRNA

Noncapped genomic RNA

nsP

Nonstructural protein

OAS2

2'-5'-Oligoadenylate Synthetase 2

ONNV

O’nyong’nyong virus

PAMP

Pathogen-associated molecular pattern

PBS

Phosphate Buffered Saline

PFU

Plaque Forming Units

PNK

Polynucleotide Kinase

qPCR

Quantitative Polymerase Chain Reaction

qRT-PCR

Quantitative Real Time Polymerase Chain Reaction

RdRp

RNA dependent RNA polymerase

RIG-I

Retinoic acid-inducible gene-I

RppH

RNA 5’ Pyrophosphohydrolase

RRV

Ross River virus

RT

Reverse Transcription

SAM

S-adenosylmethionine

SFV

Semliki Forest virus

SINV

Sindbis virus

SOCS

Suppressor of Cytokine Signaling

ssRNA

Single-stranded RNA

STAT

Signal transducer and activator of transcription protein

TF

Transframe protein

TGFb

Transforming Growth Factor beta
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TNFa

Tumor Necrosis Factor alpha

Tyk2

Tyrosine Kinase 2

VEEV

Venezuelan Equine Encephalitis virus

vRNA

viral RNA

WEEV

Western Equine Encephalitis virus

WT

Wild type

XRN-1

5'-3' exoribonuclease 1
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